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BACKGROUND. The American Cancer Society, the Centers for Disease Control and
Prevention, the National Cancer Institute, and the North American Association of
Central Cancer Registries collaborate annually to provide updated information on
cancer occurrence and trends in the U.S. The 2007 report features a comprehensive
compilation of cancer information for American Indians and Alaska Natives (AI/AN).
METHODS. Cancer incidence data were available for up to 82% of the U.S. popula-
tion. Cancer deaths were available for the entire U.S. population. Long-term
(1975 through 2004) and fixed-interval (1995 through 2004) incidence and mor-
tality trends were evaluated by annual percent change using regression analyses
(2-sided P < .05). Cancer screening, risk factors, socioeconomic characteristics,
incidence data, and stage were compiled for non-Hispanic whites (NHW) and
AI/AN across 6 regions of the U.S.
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RESULTS. Overall cancer death rates decreased by 2.1% per year from 2002
through 2004, nearly twice the annual decrease of 1.1% per year from 1993
through 2002. Among men and women, death rates declined for most cancers.
Among women, lung cancer incidence rates no longer were increasing and death
rates, although they still were increasing slightly, were increasing at a much
slower rate than in the past. Breast cancer incidence rates in women decreased
3.5% per year from 2001 to 2004, the first decrease observed in 20 years. Colorec-
tal cancer incidence and death rates and prostate cancer death rates declined,
with colorectal cancer death rates dropping more sharply from 2002 through
2004. Overall, rates for AI/AN were lower than for NHW from 1999 through 2004
for most cancers, but they were higher for cancers of the stomach, liver, cervix,
kidney, and gallbladder. Regional analyses, however, revealed high rates for AI/
AN in the Northern and Southern Plains and Alaska. For cancers of the breast,
colon and rectum, prostate, and cervix, AI/AN were less likely than NHW to be
diagnosed at localized stages.
CONCLUSIONS. For all races/ethnicities combined in the U.S., favorable trends in
incidence and mortality were noted for lung and colorectal cancer in men and
women and for breast cancer in women. For the AI/AN population, lower overall
cancer incidence and death rates obscured important variations by geographic
regions and less favorable healthcare access and socioeconomic status. Enhanced
tobacco control and cancer screening, especially in the Northern and Southern
Plains and Alaska, emerged as clear priorities. Cancer 2007;110:2119–52.
Published 2007 by the American Cancer Society.*
KEYWORDS: cancer, incidence, mortality, American Indian, Alaska Native, National
Program of Cancer Registries, Surveillance, Epidemiology, and End Results, Amer-
ican Cancer Society, North American Association of Central Cancer Registries,
U.S., health disparity.
T he American Cancer Society (ACS), the Centersfor Disease Control and Prevention (CDC), the
National Cancer Institute (NCI), and the North Amer-
ican Association of Central Cancer Registries
(NAACCR) collaborate annually to assess the cancer
burden in the U.S. The 1998 report documented the
first sustained decline in cancer death rates since the
1930s.1 Subsequent reports updated information on
trends in incidence and death rates and featured
timely, in-depth analyses of selected topics.2–9 The
American Indian and Alaska Native (AI/AN) cancer
experience has not been described well except for a
few geographic areas. This 2007 report updates the
cancer profile for the U.S. and describes regional pat-
terns of cancer in AI/AN using methods that mitigate
the effects of race misclassification.
MATERIALS AND METHODS
Cancer Cases, Cancer Deaths, and
Population Estimates
Population-based cancer registries collect informa-
tion on all reportable cancer cases. They participate
in the CDC’s National Program of Cancer Registries
(NPCR), in the NCI’s Surveillance, Epidemiology, and
End Results (SEER) Program, or both; and all are
members of NAACCR. In this report, incidence data
from these registries refer to invasive cancers, with
the exception of in situ cancer of the urinary bladder
(bladder). Primary cancer site and histology data
were coded according to the International Classifica-
tion of Diseases (ICD) for Oncology (ICD-O) edition
in use at the time of diagnosis, converted to the
Third Edition coding10 and categorized according to
SEER site groups.11
U.S. cancer deaths, reported to state vital statis-
tics offices and consolidated through CDC’s National
Vital Statistics System,12 were coded using the ver-
sion of the ICD in use at the time of death.13–16
Underlying causes of cancer death were grouped
according to the SEER cause of death recode for
maximum comparability among ICD versions.11 Mor-
tality data were provided by all 50 states and the Dis-
trict of Columbia; however, death rates for the
Hispanic population did not include data from 5
states (Maine, Minnesota, New Hampshire, North
Dakota, and Oklahoma) because of incomplete ethni-
city information for at least one of the reporting
years in the analyses.17
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County level population estimates from the U.S.
Bureau of the Census, modified by NCI, were used as
denominators in the rate calculations.18 Because the
2000 census allowed respondents to identify them-
selves as multiracial, CDC’s National Center for
Health Statistics collaborated with the Census Bureau
to develop bridging methods for single-race esti-
mates to describe long-term trends in disease.19 The
bridged, single-race annual population estimates
were used for the years 1990 through 2004.
All analyses (long-term trends, fixed-interval
trends, and average annual rates) were based on inci-
dence data for various geographic areas. Incidence
data were not available uniformly for all populations,
time periods, and geographic areas. Long-term inci-
dence trends (1975 through 2004) for all races/ethni-
cities combined by sex for all sites combined and the
15 most common cancers were based on SEER inci-
dence data covering approximately 10% of the U.S.
population, the only source for long-term incidence
analyses.20 Fixed-interval trends (1995 through 2004)
for all race/ethnic populations combined and for
white, black, Asian/Pacific Islander (API), Hispanic,
and non-Hispanic populations for all sites combined
and for the 15 most common cancers were based on
data from 24 cancer registries covering approxi-
mately 59% of the U.S. population. Average-annual
(2000 through 2004), sex-specific, and age-adjusted
incidence rates for white, black, API, Hispanic, and
non-Hispanic populations were based on incidence
data from 39 cancer registries, covering approxi-
mately 82% of the U.S. population. For the AI/AN
population, data for 2 geographic catchment areas
are presented for fixed-interval trends and rates. The
first includes AI/AN data from all counties in states
that were included in the analytic dataset. The sec-
ond includes only data from Indian Health Service
(IHS) Contract Health Service Delivery Area (CHSDA)
counties in the states that were included in the ana-
lytic dataset (see ‘‘Data for AI/AN’’ below, for an ex-
planation of CHSDA) (Table 1). Because the AI/AN
population is smaller proportionally than the other
major race/ethnic populations, 6 years of data (1999
through 2004) were used for AI/AN incidence and
death rates to increase the precision of the estimates.
All registry data included in the analyses met
NAACCR’s standards for high-quality cancer inci-
dence data. The percent of population coverage for
each of the cancer incidence datasets used for the
tables in this report are summarized in Table 1,
including the percentage of the AI/AN population
covered by each.
TABLE 1
U.S. Population Coverage for Data Sets Used in Cancer Incidence Analyses by Race/Ethnicity
Race/ethnicity
Incidence trends Incidence rates
Long-term trends Fixed-interval trends
2000–2004
39 Statesb
%d
AI/AN AI/AN (CHSDA Counties)
1975–2004
SEERa
%d
1995–2004
24 Statesb
%d
1999–2004
41 Statesb,c
%d
1999–2004
30 Statesb,c
%d
2001–2003
30 Statesb,c
%d
(Table 2) (Table 4) (Table 4) (Table 4) (Tables 4,7,8) (Table 9)
All race/ethnic groups 9.4 59.3 81.8
White 58.8 82.1
Black 56.0 77.9
API 80.6 89.7
AI/AN 48.5 87.7
AI/AN (CHSDA counties) 20.7e 52.1 52.7
Hispanic 84.6 91.0
Non-Hispanic 55.7 80.4
Non-Hispanic white 19.8 20.2
AI/AN indicates American Indian and Alaska Native; CHSDA, Indian Health Service Contract Health Service Delivery Area; SEER, Surveillance, Epidemiology, and End Results; NPCR, National Program of Cancer
Registries; NAACCR, North American Association of Central Cancer Registries.
a SEER areas include Connecticut, Hawaii, Iowa, Utah, and New Mexico and the metropolitan areas of San Francisco, Detroit, Atlanta, and Seattle-Puget Sound (ie SEER 9).
b NPCR and SEER areas with cancer registry data reported by the NAACR as meeting high-quality standards for the specified period.
c The Wisconsin and Arizona data for the specified period are used for AI/AN as well as AI/AN and non-Hispanic white in CHSDA counties only.
d Percentage of the U.S. population.
e Data from 17 states that met high-quality standards for the specified period.
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Classification of American Indian and
Alaska Native Race
Race generally is documented by cancer registries
based on the patient’s medical record; however, it
has been determined that many AI/AN were misclas-
sified as non-Native in some central cancer regis-
tries21–26 and in state death records.27 Such
misclassification leads to underestimation of the true
burden of cancer in AI/AN populations.
To improve race classification for AI/AN cases,
all records for cases diagnosed from 1995 through
2004 were linked with the IHS patient registration
database to identify AI/AN cases that were misclassi-
fied as non-Native. The IHS provides medical ser-
vices to AI/AN persons who are members of federally
recognized tribes. Membership criteria are deter-
mined by individual tribes and typically refer to a
percentage of ‘‘blood quantum’’ or fraction of AI/AN
ancestry, with some tribes requiring only proof of
descent from an AI/AN ancestor, whereas others
may require as much as one-half ancestry (one-half
blood quantum).28 The patient registration database
includes persons who have received services since
1985 provided either in an IHS and/or tribal facility
or by a non-IHS or nontribal program and paid by
IHS Contract Health Services funds. A small number
of non-AI/AN persons are eligible for IHS services
through marriage or other basis; these records were
removed before linkage with the registries. Linkages
were conducted using LinkPlus, a probabilistic link-
age software program that was developed by CDC
that was applied to key patient identifiers (Social Se-
curity number, first name, last name, middle initial,
date of birth, and date of death).29 Possible matches,
requiring manual review, were examined independ-
ently by 2 reviewers and, when necessary, were adju-
dicated by a third reviewer.
The cancer incidence rates in this report use in-
formation from the IHS linkage in combination with
information from the race variables that are reported
routinely by the central cancer registries. Beginning
with cancer cases diagnosed on January 1, 2000 and
later, registries report data in multiple race fields for
multiracial individuals if that information is available
from medical records.30 Coding rules specify that, for
persons of multiple races, a nonwhite race takes pri-
ority over white race for analytic purposes.31 For this
report, all cases classified as AI/AN in the first race
field were retained in that category. In addition,
when the first race field was classified as white or
unknown and there was a positive IHS link, then the
case also was reclassified as AI/AN for this report. If
the first race field was coded as API, black, or other
race and there was a positive IHS link, then the value
for first race was retained.
Data for American Indians and Alaska Natives
For the AI/AN population in this report, emphasis is
placed on data from IHS CHSDA counties, which, in
general, contain federally recognized tribal lands or
are adjacent to tribal lands (Fig. 1). Unpublished data
indicate less race misclassification for AI/AN in these
counties than in non-CHSDA counties. Also, the
proportions of AI/AN in relation to total population
are higher in CHSDA counties than in non-CHSDA
counties; 57% of the U.S. AI/AN population resides
in the 624 counties designated as CHSDA (Table 1
Supplement A, which shows the AI/AN population by
region and residence in CHSDA county, is available
at URL: www.seer.cancer.gov/report_to_nation/).
Analyses restricted to CHSDA counties are presented
for cancer incidence and death rates and stage distri-
bution in this report to improve accuracy in inter-
preting cancer statistics for AI/AN persons (for
distribution of CHSDA counties, see Fig. 1). All
results described in the text for AI/AN refer to AI/AN
persons who reside in CHSDA counties unless noted
otherwise.
The analysis of AI/AN data by IHS region
(Alaska, Pacific Coast, Northern Plains, Southern
Plains, Southwest, and East) (Fig. 1) was consistent
with known regional trends for specific health out-
comes and risk factors for AI/AN. Regional analyses
have been presented in several publications focusing
on AI/AN,32–35 and this approach was preferable to
the use of smaller jurisdictions, such as the Adminis-
trative Areas defined by IHS,36 which yielded less
stable estimates. Supplemental information regarding
population coverage and other measures of the bur-
den of cancer in the AI/AN by IHS region is con-
tained in a Table on the NCI web site (available at
URL: www.seer.cancer.gov/report_to_nation/). Addi-
tional data regarding cancer incidence and mortality
are available from the following sites: www.cancer.-
gov (NCI), www.cancer.org (ACS), www.cdc.gov/can-
cer/npcr/index.htm and www.cdc.gov/nchs/about/
major/dvs/mortdata.htm (CDC), and www.naaccr.
org/CINAP?index.htm (NAACCR).
Socioeconomic Status, Healthcare Access, Risk Factors,
Screening, and Stage
Data regarding socioeconomic status, healthcare
access, behavioral risk factors, and cancer screening
by race/ethnicity and geographic region were ob-
tained from the U.S. Census Bureau and the CDC’s
Behavioral Risk Factor Surveillance System (BRFSS)
and were categorized according to Healthy People
2010 objectives.37 Questions concerning cigarette
smoking, physical activity, alcohol consumption, and
Papanicolaou (Pap) tests (women only) were asked of
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adults aged 18 years. Questions also were asked
regarding participation in mammography screening
among women aged 40 years, colorectal cancer
screening among persons aged 50 years, and pros-
tate-specific antigen (PSA) testing among men aged
50 years who reported no history of prostate can-
cer. Adults aged 20 years were asked about self-
reported obesity prevalence.
The distribution of stage of disease at diagnosis
for cancers of the breast, prostate, colon and rectum,
and cervix uteri (cervix) was examined for non-His-
panic white (NHW) and AI/AN populations region-
ally and in all regions combined. Cancer incident
cases were staged using the 2000 SEER Summary
Stage. To eliminate the effect of different staging sys-
tems both before 2001 and after 2003, only indivi-
duals who were diagnosed from 2001 through 2003
were included for cancer stage statistics.38
Statistical Analysis
For all populations, cancer incidence and death rates
were expressed per 100,000 persons and were age-
adjusted by 19 age groups (aged < 1 year, ages 1–4
years, ages 5–9 years, . . ., ages 80–84 years, aged 85
years) to the 2000 U.S. standard population. Age
adjustment summarizes age-specific rates and elimi-
nates the effect of differences in age composition
among the populations being compared.39 The AI/
AN population is younger on average than the NHW
population.40 Rates, standard errors, and 95% confi-
dence intervals (95% CIs) were generated using
SEER*Stat software, version 6.3 (available at URL:
http://www.seer.cancer.gov/seerstat/).20 All incidence
and death rates that were calculated with < 16
observations were suppressed. Similarly, the annual
percent change (APC) statistic was suppressed if it
was based on < 10 cases for at least 1 year within
the time interval.
Long-term cancer incidence and death trends
(1975 through 2004) were described using joinpoint
analysis, including the APC for each interval, for all
races/ethnicities combined.41 Statistical significance
was set at P < .05. The observed incidence trends
and those adjusted for reporting delay (mostly
affecting recent years) were presented using models
based on long-term reporting patterns in SEER.42
Nondelay-adjusted and delay-adjusted APCs are pre-
sented; however, only delay-adjusted results are
referred to in the text. APC analysis was used to
describe fixed interval trends (1995 through 2004);
the incidence data for the fixed interval APCs were
not adjusted for reporting delay. For both methods
of trend analysis, the terms ‘‘increase’’ or ‘‘decrease’’
were used when the slope of the trend was statisti-
cally significant (P < .05); otherwise, the terms
‘‘stable’’ or ‘‘level’’ were used.
FIGURE 1. States and Contract Health Service Delivery Area (CHSDA) counties used in cancer incidence analyses for the American Indian/Alaska Native popu-
lation, by Indian Health Service region.
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Prevalence estimates for screening and risk fac-
tors were calculated using data from the BRFSS
aggregated over the 6-year period 1999 through 2005.
Not all years were available for each BRFSS-derived
risk factor, because some questions were not asked
every year. Prevalence estimates from BRFSS were
age-adjusted to the 2000 U.S. standard population
and sample-weighted using SUDAAN software to
account for the complex BRFSS sampling design.43
Prevalence estimates for cancer risk factors and
screening were suppressed if they were based
on < 50 observations. Prevalence estimates of socio-
economic characteristics from U.S. Census were not
age-adjusted. Confidence intervals are provided for
all prevalence estimates; however, they do not pro-
vide a basis for significance testing of regional differ-
ences.44
Regional, site-specific comparisons of incidence
rates between AI/AN and NHW populations are
shown by rate ratios (RR) with 95% CIs. In describing
rate comparisons for AI/AN and NHW populations,
the terms ‘‘higher’’ or ‘‘lower’’ were used when the
RRs differed significantly from 1.0 (P < .05). Thus,
when the RR was < 1.0, the rate among AI/AN was
lower than that among NHW; when the RR
was > 1.0, the rate among AI/AN was higher than
that among NHW. Otherwise, the RRs were described
as comparable. Relative percents (R%) were cal-
culated to facilitate comparisons of distributions of
age-adjusted, stage-specific incidence rates between
NHW and AI/AN populations across IHS regions.
RESULTS
Update on Long-term Incidence Trends, 19752004
For all populations, both sexes, and all cancer sites
combined, incidence rates increased from 1975
through 1992 and then decreased (0.3% per year)
from 1992 through 2004 (Table 2). For men, the rates
increased from 1975 through 1992, decreased from
1992 through 1995, and subsequently stabilized from
1995 through 2004. For women, rates increased from
1979 through 1986, increased more slowly from 1986
through 1999, and stabilized from 1999 through
2004.
Among men, prostate cancer incidence rates sta-
bilized from 1995 through 2004 after the steep
increase reported from 1988 through 1992 and the
subsequent decline from 1992 through 1995.
Increases in cancer incidence were noted from 1975
through 2004 for myeloma and for cancers of the
kidney and renal pelvis (kidney), liver and intrahe-
patic bile ducts (liver), and esophagus. Declining
trends in incidence were noted for the most recent
joinpoint segments for cancers of the lung and
bronchus (lung), colon and rectum, oral cavity and
pharynx (oral cavity), and stomach. Rates were stable
for the most recent joinpoint segments for the
remaining top 15 cancers in men.
Among women, breast cancer incidence rates
decreased for the period 2001 through 2004 by 3.5%
per year, reversing a long-term increase that began
in the early 1980s. Lung cancer rates increased from
1975 through 1998 and stabilized from 1998 through
2004. Colorectal cancer rates decreased from 1998
through 2004. Rates also declined for cancers of the
cervix and stomach from 1975 through 2004 and for
cancers of the corpus uteri and uterus not otherwise
specified (uterus), ovary, and oral cavity in the most
recent joinpoint segments. Increasing trends were
noted from 1975 through 2004 for melanoma, non-
Hodgkin lymphoma (NHL), leukemia, and cancers of
the bladder and kidney. Increasing rates of thyroid
cancer were noted from 1980 through 1995, with the
rate of increase nearly tripling from 1995 through
2004. Pancreatic cancer incidence rates stabilized for
the most recent joinpoint segment.
Update on Long-term Mortality Trends,
19752004
Cancer death rates for all races/ethnicities and both
sexes combined decreased by 2.1% per year from
2002 to 2004 compared with 1.1% per year from 1993
to 2002 (Table 3). The decreases involved both men
and women, but they were greater in men than in
women from 2002 through 2004 (2.6% per year in
men and 1.8% per year in women). Accelerated
declines in cancer mortality rates largely reflect more
rapid decreases in the death rates from leading
causes of cancer mortality: lung and prostate cancer
in men, breast cancer in women, and colon and rec-
tum cancer in both men and women.
During the last joinpoint segment, rates were
declining for 12 of the 15 most common causes of
cancer death in men (lung, prostate, colon and rec-
tum, pancreas, leukemia, NHL, bladder, kidney,
stomach, brain, myeloma, and oral cavity) (Table 4).
Melanoma rates remained stable from 1990 through
2004. The rates for only 2 sites—cancer of the liver
and esophagus—increased (1.8% and 0.4% per year,
respectively).
Similarly, rates declined for 10 of the 15 most
common causes of cancer death in women (breast,
colon and rectum, NHL, leukemia, brain, myeloma,
stomach, kidney, cervix, and bladder). Death rates for
the most recent joinpoint segments were stable in
women for cancers of the pancreas, ovary, and
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TABLE 2
Surveillance, Epidemiology, and End Results Cancer Incidence Rate Trends With Joinpoint Analyses for 1975–2004 for the Top 15 Cancers,
by Sex, for All Races
Sex/cancer site or type
Joinpoint analyses (1975–2004)a
Trend 1 Trend 2 Trend 3 Trend 4
Years APCd Years APCd Years APCd Years APCd
All sitesb
Both sexes 1975–1992 1.4e 1992–1995 1.3 1995–2001 0.3 2001–2004 2.1e
(Delay-adjusted) 1975–1992 1.4e 1992–2004 0.3e
Males 1975–1989 1.3e 1989–1992 5.0e 1992–1995 4.1e 1995–2004 0.5e
(Delay-adjusted) 1975–1989 1.3e 1989–1992 5.1e 1992–1995 4.3e 1995–2004 0.2
Females 1975–1979 0.2 1979–1987 1.5e 1987–2001 0.3e 2001–2004 1.7e
(Delay-adjusted) 1975–1979 0.3 1979–1986 1.6e 1986–1999 0.4e 1999–2004 0.5
Top 15 cancers for malesc
Prostate 1975–1988 2.6e 1988–1992 16.2e 1992–1995 10.1e 1995–2004 0.1
(Delay-adjusted) 1975–1988 2.6e 1988–1992 16.2e 1992–1995 10.2e 1995–2004 0.4
Lung and bronchus 1975–1982 1.4e 1982–1991 0.4 1991–2004 1.9e
(Delay-adjusted) 1975–1982 1.5e 1982–1991 0.5 1991–2004 1.8e
Colon and rectum 1975–1986 1.1e 1986–1995 2.1e 1995–1998 1.1 1998–2004 2.8e
(Delay-adjusted) 1975–1986 1.1e 1986–1995 2.1e 1995–1998 1.1 1998–2004 2.6e
Urinary bladder 1975–1987 1.0e 1987–1995 0.6 1995–2000 1.1 2000–2004 1.6e
(Delay-adjusted) 1975–1987 1.0e 1987–1996 0.5 1996–1999 2.0 1999–2004 0.9
Non-Hodgkin lymphoma 1975–1991 4.3e 1991–2004 0.1
(Delay-adjusted) 1975–1991 4.2e 1991–2004 0.3
Melanoma of the skin 1975–1985 5.4e 1985–2000 3.3e 2000–2004 0.0
(Delay-adjusted) 1975–1985 5.4e 1985–2000 3.4e 2000–2004 0.5
Kidney and renal pelvis 1975–2004 1.7e
(Delay-adjusted) 1975–2004 1.8e
Leukemia 1975–2001 0.1 2001–2004 3.2
(Delay-adjusted) 1975–2004 0.1
Oral cavity and pharynx 1975–1983 0.1 1983–2004 1.5e
(Delay-adjusted) 1975–1983 0.2 1983–2004 1.4e
Pancreas 1975–1993 0.8e 1993–2004 0.1
(Delay-adjusted) 1975–1993 0.9e 1993–2004 0.3
Stomach 1975–1988 1.2e 1988–2004 2.1e
(Delay-adjusted) 1975–1988 1.2e 1988–2004 2.0e
Liver and intrahepatic bile duct 1975–1986 2.1e 1986–1996 5.0e 1996–2004 2.1e
(Delay-adjusted) 1975–1986 2.1e 1986–1996 4.9e 1996–2004 2.5e
Brain and other nervous system 1975–1991 1.1e 1991–2004 0.7e
(Delay-adjusted) 1975–1991 1.0e 1991–2004 0.6
Esophagus 1975–2004 0.8e
(Delay-adjusted) 1975–2004 0.8e
Myeloma 1975–1991 1.3e 1991–2004 0.1
(Delay-adjusted) 1975–2004 0.8e
Top 15 cancers for femalesc
Breast 1975–1980 0.4 1980–1987 3.7e 1987–2001 0.4e 2001–2004 3.9e
(Delay-adjusted) 1975–1980 0.4 1980–1987 3.7e 1987–2001 0.5e 2001–2004 3.5e
Lung and bronchus 1975–1982 5.5e 1982–1990 3.5e 1990–1998 1.0e 1998–2004 0.5
(Delay-adjusted) 1975–1982 5.5e 1982–1990 3.5e 1990–1998 1.0e 1998–2004 0.1
Colon and rectum 1975–1985 0.3 1985–1995 1.9e 1995–1998 1.9 1998–2004 2.4e
(Delay-adjusted) 1975–1985 0.3 1985–1995 1.8e 1995–1998 1.8 1998–2004 2.2e
Corpus and uterus, NOS 1975–1979 6.0e 1979–1988 1.7e 1988–1998 0.6e 1998–2004 1.0e
(Delay-adjusted) 1975–1979 6.0e 1979–1988 1.7e 1988–1998 0.6e 1998–2004 0.8e
Non-Hodgkin lymphoma 1975–1990 2.9e 1990–2004 1.1e
(Delay-adjusted) 1975–1988 3.0e 1988–2004 1.4e
Melanoma of the skin 1975–1981 5.2e 1981–2004 2.2e
(Delay-adjusted) 1975–1981 5.1e 1981–2004 2.3e
Ovaryb 1975–1985 0.1 1985–2001 0.7e 2001–2004 3.5e
(Delay-adjusted)b 1975–1987 0.1 1987–2004 0.9e
(continued)
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uterus. Lung cancer death rates have increased since
1975. However, the rate of increase has slowed over
time to 0.2% annually from 1995 to 2004. Finally,
from 2001 through 2004, liver cancer rates increased
2.6% annually in women.
Cancer Incidence Rates, 20002004 and Fixed Interval
Trends, 19952004
Table 4 presents cancer incidence for the 15 most
common cancers for each sex, for all races/ethnici-
ties combined, and for the 6 major race/ethnic
populations. In men, the 3 leading incident cancers
were prostate, lung, and colon and rectum in all
race/ethnic populations, although colorectal cancer
ranked second and lung cancer ranked third among
Hispanic men. For most men, bladder cancer and
NHL were the fourth and fifth leading incident can-
cers. However, cancers of the kidney and bladder
ranked fourth and fifth for black and AI/AN men,
and liver and stomach ranked fourth and fifth for
API men.
Cancer incidence trends for men in all race/eth-
nic groups combined decreased from 1995 through
2004. Among men, incidence rates of cancers of the
lung, larynx, and stomach decreased in each race/
ethnic population for which the APC was presented.
Prostate cancer rates decreased for black and AI/AN
men but were stable for white, API, Hispanic, and
non-Hispanic men. Colorectal cancer incidence
rates decreased for white, API, and non-Hispanic
men and remained stable for black, AI/AN, and His-
panic men. Increases were noted for kidney and
liver cancer in men except API and AI/AN men, in
whom the rates remained stable. Thyroid cancer
showed the largest annual increases in populations
for which the APC was presented. Melanoma rates
increased in white and non-Hispanic men, were
stable in API and Hispanic men, and decreased in
black men.
Among women, the 4 leading incident cancers
from 2000 through 2004 were breast, lung, colon and
rectum, and uterus across all race/ethnic popula-
tions (Table 4). NHL was ranked fifth for all popula-
tions except black, API, and AI/AN women. Cancer
of the pancreas ranked fifth for black women, thyr-
oid cancer ranked fifth for API women, and kidney
TABLE 2
(continued)
Sex/cancer site or type
Joinpoint analyses (1975–2004)a
Trend 1 Trend 2 Trend 3 Trend 4
Years APCd Years APCd Years APCd Years APCd
Thyroid 1975–1977 6.5 1977–1980 5.3 1980–1995 2.3e 1995–2004 5.9e
(Delay-adjusted) 1975–1977 6.5 1977–1980 5.3 1980–1995 2.3e 1995–2004 6.1e
Pancreas 1975–1983 1.4e 1983–2004 0.2
(Delay-adjusted) 1975–1983 1.3e 1983–2004 0.1
Leukemia 1975–2004 0.1
(Delay-adjusted) 1975–2004 0.2e
Urinary bladder 1975–2004 0.1e
(Delay-adjusted) 1975–2004 0.2e
Cervix uteri 1975–1981 4.6e 1981–1996 1.1e 1996–2004 3.9e
(Delay-adjusted) 1975–1981 4.6e 1981–1996 1.1e 1996–2004 3.7e
Kidney and renal pelvis 1975–2004 2.2e
(Delay-adjusted) 1975–2004 2.3e
Oral cavity and pharynx 1975–1980 2.7e 1980–2004 1.0e
(Delay-adjusted) 1975–1980 2.6e 1980–2004 1.0e
Stomach 1975–2004 1.6e
(Delay-adjusted) 1975–2004 1.6e
Source: Surveillance, Epidemiology, and End Results (SEER) 9 areas covering about 10% of the U.S. population (Connecticut, Hawaii, Iowa, Utah, and New Mexico and the metropolitan areas of San Francisco,
Detroit, Atlanta, and Seattle-Puget Sound).
APC indicates annual percent change; NOS, not otherwise specified.
a Joinpoint analyses with up to 3 joinpoints are based on rates per 100,000 persons and were age-adjusted to the 2000 U.S. standard population (19 age groups, Census p25–1130; Jointpoint [JP] Regression Pro-
gram, Version 3.0; National Cancer Institute, April, 2005).
b All sites excludes myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.
c The top 15 cancers were selected based on the sex-specific, age-adjusted incidence rates for 2000–2004 for all races combined and are listed in rank order.
d APC is based on rates that were age-adjusted to the 2000 U.S. standard population (19 age groups; Census, p25–1130).
e APC is statistically significantly different from zero (2-sided P < .05).
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cancer ranked fifth for AI/AN women. The rank-
ing of cancers beyond the top 5 varied by race/eth-
nicity.
Cancer incidence trends for women for all race/
ethnicities combined were stable from 1995 through
2004. Although breast cancer rates for all races com-
bined from 1995 through 2004 appeared stable, the
use of joinpoint methods revealed that the trend did
change in 2001, with a statistically significant decline
of 3.4% per year from 2001 through 2004 (data not
shown), comparable to the long-term trend results
based on SEER data. Hispanic women experienced a
decrease in breast cancer incidence rates from 1995
through 2004, and rates for AI/AN women were
TABLE 3
U.S. Death Rate Trends With Joinpoint Analyses for 1975–2004 for the Top 15 Cancers, by Sex, for All Races
Sex/cancer site or type
Joinpoint analyses (1975–2004)a
Trend 1 Trend 2 Trend 3 Trend 4
Years APCc Years APCc Years APCc Years APCc
All sites
Both sexes 1975–1990 0.5d 1990–1993 0.3 1993–2002 1.1d 2002–2004 2.1d
Males 1975–1980 0.9d 1980–1992 0.3d 1992–2002 1.5d 2002–2004 2.6d
Females 1975–1990 0.6d 1990–1994 0.2 1994–2002 0.8d 2002–2004 1.8d
Top 15 cancers for malesb
Lung and bronchus 1975–1982 1.7d 1982–1990 0.5d 1990–1994 1.3d 1994–2004 2.0d
Prostate 1975–1987 0.9d 1987–1991 3.0d 1991–1994 0.5 1994–2004 4.1d
Colon and rectum 1975–1979 0.6 1979–1987 0.6d 1987–2002 1.9d 2002–2004 4.9d
Pancreas 1975–1986 0.9d 1986–2004 0.2d
Leukemia 1975–1995 0.2d 1995–2004 0.8d
Non-Hodgkin lymphoma 1975–1981 1.8d 1981–1990 3.0d 1990–1997 1.6d 1997–2004 3.0d
Esophagus 1975–1985 0.7d 1985–1994 1.2d 1994–2004 0.4d
Urinary bladder 1975–1983 1.4d 1983–1987 2.7d 1987–1993 0.1 1993–2004 0.6d
Liver and intrahepatic bile duct 1975–1985 1.5d 1985–1995 3.8d 1995–2004 1.8d
Kidney and renal pelvis 1975–1992 1.1d 1992–2004 0.3d
Stomach 1975–1987 2.3d 1987–1991 0.9 1991–2004 3.5d
Brain and other nervous system 1975–1977 4.4 1977–1982 0.3 1982–1991 1.3d 1991–2004 0.9d
Myeloma 1975–1994 1.5d 1994–2004 1.1d
Oral cavity and pharynx 1975–1980 0.8 1980–2004 2.2d
Melanoma of the skin 1975–1990 2.2d 1990–2004 0.0
Top 15 cancers for femalesb
Lung and bronchus 1975–1982 6.0d 1982–1990 4.2d 1990–1995 1.7d 1995–2004 0.2d
Breast 1975–1990 0.4d 1990–2004 2.2d
Colon and rectum 1975–1984 1.0d 1984–2002 1.8d 2002–2004 4.5d
Pancreas 1975–1984 0.8d 1984–2004 0.1
Ovary 1975–1982 1.2d 1982–1992 0.3 1992–1998 1.1d 1998–2004 0.2
Non-Hodgkin lymphoma 1975–1995 2.2d 1995–1998 0.3 1998–2004 3.8d
Leukemia 1975–1980 0.8 1980–2001 0.4d 2001–2004 2.4d
Corpus and uterus, NOS 1975–1992 1.5d 1992–2004 0.0
Brain and other nervous system 1975–1992 0.9d 1992–2004 1.0d
Myeloma 1975–1993 1.5d 1993–2001 0.4 2001–2004 2.4d
Liver and intrahepatic bile duct 1975–1987 0.8d 1987–1995 3.8d 1995–2001 0.3 2001–2004 2.6d
Stomach 1975–1987 2.8d 1987–1990 0.5 1990–2004 2.6d
Kidney and renal pelvis 1975–1992 1.3d 1992–2004 0.5d
Cervix uteri 1975–1982 4.3d 1982–1996 1.6d 1996–2004 3.7d
Urinary bladder 1975–1986 1.7d 1986–2004 0.4d
Source: National Center for Health Statistics public-use data file for the total U.S.
APC indicates annual percent change; NOS, not otherwise specified.
a Joinpoint analyses with up to 3 joinpoints are based on rates per 100,000 persons and were age-adjusted to the 2000 U.S. standard population (19 age groups, Census p25–1130; Jointpoint [JP] Regression Pro-
gram, Version 3.0; National Cancer Institute, April, 2005).
b The top 15 cancers were selected based on the sex-specific, age-adjusted incidence rates for 2000–2004 for all races combined and are listed in rank order.
c APC is based on rates that were age-adjusted to the 2000 U.S. standard population (19 age groups; Census, p25–1130).
d APC is statistically significantly different from zero (2-sided P < .05).
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stable. White, API, and non-Hispanic women experi-
enced a decrease in cancer of the colon and rectum,
whereas the rates for black, AI/AN, and Hispanic
women remained stable. Uterine cancer decreased
among white women, increased among black and
Hispanic women, and was stable for API and AI/AN
women. Cervical cancer declined for all race/ethnic
populations except AI/AN women, in whom it was
stable, as did stomach cancer for all except Hispanic
women, in whom rates were stable. Ovarian cancer
decreased in white, API, and non-Hispanic women
and remained stable in black, AI/AN, and Hispanic
women. The use of joinpoint methods for the period
from 1995 through 2004 revealed a 1.0% decline per
year in ovarian cancer incidence from 1995 through
2001 and an increased rate of decline of 3.3% per
year from 2001 through 2004 for all races combined
(data not shown); this increased rate of decline was
confined to white women. Similar patterns were
observed for uterine cancer (data not shown). Thyr-
oid cancer rates had the largest annual increase
(7.0% per year).
Update on Cancer Death Rates, 20002004 and Fixed
Interval Trends, 19952004
Among men, overall cancer death rates from 2000
through 2004 were highest for black men and lowest
for API men (Table 5). Cancers of the lung, prostate,
and colon and rectum were the leading causes of
cancer death from 2000 through 2004 among men
for all race/ethnic populations except API men, in
whom cancer of the liver ranked second. Beyond the
top 3 sites, race-specific rankings varied.
For men of most race/ethnic populations, trends
of all cancers combined and trends of the 3 leading
causes of cancer death declined from 1995 through
2004. For AI/AN men, trends in death rates were
level for all cancers combined, prostate cancer, and
colorectal cancer and declined for lung cancer.
Among women, overall cancer death rates from
2000 through 2004 were highest for black women
and lowest for API and Hispanic women (Table 5).
Among all race/ethnic populations, cancer of the
lung ranked first in cause of death, breast cancer
ranked second, and colorectal cancer ranked third
with the exception of Hispanic women, for whom
breast cancer ranked first and lung cancer ranked
second. Similar to men, among women, race-specific
rankings of less common cancers varied. From 1995
through 2004, women experienced a smaller decrease
than men in death rates for all cancers combined
(1.0% per year vs 1.7% per year, respectively). Simi-
larly, the slight increase in lung cancer mortality in
women (0.2% per year) contrasted with the substan-
tial decrease in men (2.0% per year). A comparison
of death rates from 2000 through 2004 for all cancer
sites combined showed that API women had the lar-
gest annual decline (1.4% per year), and AI/AN
women had a stable death rate.
SPECIAL SECTION: CANCER AMONG AMERICAN
INDIANS AND ALASKA NATIVES, 19992004
General Characteristics
The 2004 intercensal population estimates of 3.3 mil-
lion AI/AN persons represented 1.1% of the total U.S.
population.18 These persons are members of—or
related to—1 or more of > 550 federally recognized
or > 200 nonfederally recognized tribes with diverse
languages, cultures, and histories. The median age of
the U.S. AI/AN population was 29 years in 2000,
which was younger than the nationwide median age
of 35 years.40 Approximately 75% of the AI/AN popu-
lation reside west of the Mississippi River and is con-
centrated in Alaska, Oklahoma, and other selected
regions—the Southwest, Northern Plains, and Pacific
Northwest (Fig. 2). Approximately one-third of AI/AN
reside on tribal reservations, trust lands, or other
tribal-affiliated areas, and others live primarily in
urban areas.40,45
Socioeconomic Characteristics, Cancer Risk Factors, and
Use of Cancer Screening
Poverty among the AI/AN population was 3 times
that of the NHW population, with the Southwest AI/
AN population having the highest regional preva-
lence of poverty (Table 6). AI/AN adults were less
likely to graduate from high school and were more
likely to have less than a ninth grade education than
NHW adults, with Alaska and Southwest AI/AN
populations having the lowest formal education
attained. The percentage of AI/AN persons age < 65
years with no health coverage was twice that of
NHW adults. The proportion of persons ages 18 to 64
years with no usual source of care was higher among
the AI/AN population overall and in all regions. For
NHW and AI/AN populations in all regions, men
were more likely than women to have no usual
source of medical care. It is noteworthy that AI/AN
persons in Alaska aged 65 years reported the high-
est prevalence of no healthcare coverage; a 10-fold
higher prevalence than NHW persons aged > 65
years. Additional information regarding cancer inci-
dence and county poverty level among AI/AN and
NHW populations for selected cancer sites is avail-
able in Table Supplement-Poverty (available at URL:
www.seer.cancer.gov/report_to_nation/).
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Current smoking prevalence among persons aged
18 years was higher among AI/AN persons overall
than among NHW persons, with the highest preva-
lence among AI/AN populations in Alaska and the
Northern Plains (Table 6). Smoking prevalence
among AI/AN was the lowest in the Southwest and
did not differ greatly from that among NHW. In all
regions, more AI/AN than NHW men and women
aged 20 years reported being obese; and, corre-
spondingly, more AI/AN than NHW persons aged
18 years reported no leisure time physical activity.
Whereas heavy drinking was more common among
men than among women in both populations, the
percentage of AI/AN persons aged 18 years who
consumed 5 drinks on 1 occasion was higher over-
all than that of NHW adults. The estimates for AI/AN
in the individual regions were less stable; however, in
Alaska and in the Northern Plains, both AI/AN men
and AI/AN women had a higher prevalence of heavy
drinking than NHW. In the Southwest, this was true
for AI/AN men only.
The prevalence of cancer screening was lower
among AI/AN than NHW persons and varied widely
across IHS regions (Table 6). Mammography screen-
ing was lower among AI/AN women than among
NHW women, with the lowest AI/AN prevalence esti-
mates in the Pacific Coast and Southwest. Similarly,
among AI/AN men and women aged 50 years, fecal
occult blood testing (FOBT) and endoscopy within
the past 5 years were lower than that among NHW
men and women. The prevalence of endoscopy for
the AI/AN population in the Southwest was half the
prevalence for the NHW population. Pap testing
prevalence was lowest for AI/AN women in the
Southern Plains and the East and was higher for
Alaskan AI/AN women than for NHW women. Simi-
larly, the prevalence of PSA testing was lower for AI/
AN men than for NHW men.
Cancer Incidence
Cancer incidence rates in AI/AN persons for all can-
cers combined were lower than for NHW persons for
all regions combined (Tables 7 and 8). However, inci-
dence rates varied by geographic region and cancer
site. Among AI/AN men, cancer incidence rates for
all sites combined ranged from 262 per 100,000 men
in the Southwest to 611 per 100,000 men in the
Northern Plains compared with the rates in NHW
men, which ranged from 513 per 100,000 men in the
Southwest to 578 per 100,000 men in the East.
Among AI/AN women, the cancer incidence rates
ranged from 219 per 100,000 women in the South-
west to 511 per 100,000 women in Alaska compared
with a range from 404 per 100,000 women in theTA
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Southern Plains to 438 per 100,000 women in the Pa-
cific Coast among NHW women. In general, these re-
gional variations persisted for most cancer sites
among AI/AN populations, and incidence rates were
significantly higher among AI/AN populations in
Alaska and the Northern and Southern Plains than
among AI/AN populations in the Southwest (95% CIs
for AI/AN incidence rates for all regions combined
and individual regions are available online at URL:
www.seer.cancer.gov/report_to_nation/).
Among AI/AN men, the top 3 incident cancers
were prostate, lung, and colon and rectum for all
regions except the Southwest, where the leading can-
cers were prostate, colon and rectum, and kidney
(Table 7). Prostate cancer rates for AI/AN men were
highest in the Northern and Southern Plains and
were similar to the prostate cancer rates for NHW
men in those regions. Lung and colorectal cancer
rates were highest in the Northern Plains and Alaska
and were elevated significantly compared with NHW
men. The Southwest had the lowest rates for the top
3 sites in AI/AN men for all regions combined. Rates
of kidney cancer in AI/AN men were higher than
those in NHW men in Alaska, the Northern Plains,
the Southern Plains, and the Southwest. Stomach
cancer in AI/AN men was more than 4 times as com-
mon as in NHW men in Alaska and was twice as
common in AI/AN men in the Southwest and North-
ern Plains compared with NHW men. Cancer of the
liver was greater in AI/AN men than in NHW men in
5 regions and was highest for AI/AN men in the
Northern Plains. Gallbladder cancer in AI/AN men
was 3.7 times that of NHW men for all regions com-
bined and was 6 times greater in the Southwest, the
only individual region for which data are shown. The
incidence rates for leukemia, melanoma, and cancers
of the bladder, brain, and testis generally were lower
in AI/AN men than in NHW men.
Among AI/AN women, the 3 top cancer sites
were breast, lung, and colon and rectum in all
regions except the Southwest, where the rate for
uterine cancer ranked third (Table 8). In Alaska, the
breast cancer rate among AI/AN women was similar
to the rate among NHW women; however, in all
other regions, breast cancer was significantly lower
among AI/AN women. In the Northern Plains, the
rate of lung cancer among AI/AN women was nearly
double that among NHW women; whereas, in the
Southwest, AI/AN women had one-fifth the lung can-
cer rate of NHW women. The colorectal cancer rate
was highest among AI/AN women in Alaska (2.6
times the rate in NHW women); whereas AI/AN
women in the Southwest had less than half the color-
ectal cancer rate of NHW women. Kidney cancer
incidence for AI/AN women exceeded that for NHW
women in the Northern and Southern Plains and in
the Southwest. Stomach cancer, which was elevated
for AI/AN women overall, was nearly 6 times the rate
FIGURE 2. Percentage of the county population that is American Indian/Alaska Native, 2004. Source: 2004 Intercensal bridged single-race population esti-
mates, U.S. Census Bureau/National Cancer Institute. Available at URL: http://seer.cancer.gov/popdata/.
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for NHW women in Alaska, 3 times greater than for
NHW women in the Southwest, and 2 times greater
than for NHW women in the Northern and Southern
Plains. The rate of liver cancer among AI/AN women
ranged from 1.9 times the rate among NHW women
in the Southern Plains to 3.4 times greater in the
Northern Plains. The rate of cancer of the cervix was
elevated in AI/AN women in the Northern and
Southern Plains. The incidence rate of gallbladder
cancer was elevated in AI/AN women in the South-
ern Plains and the Southwest, whereas it was 2.7 and
7.1 times the rate of NHW women, respectively. The
incidence rates of NHL, melanoma, and bladder can-
cer generally were lower in AI/AN women than in
NHW women.
Cancer Stage
Overall, AI/AN persons were less likely than NHW
persons to be diagnosed with early stages of colorec-
tal cancer, although this pattern varied by region; the
difference between AI/AN and NHW persons was
larger in the Southwest, Northern Plains, and South-
ern Plains than in other regions (Table 9). Approxi-
mately three-fourths of prostate cancer cases were
diagnosed with localized stage among NHW men
overall and among AI/AN men in Alaska and the
Southern Plains regions. AI/AN women in all regions
were less likely than NHW women to be diagnosed
with localized breast cancer. Similarly, AI/AN women
in all regions combined were less likely than NHW
women to be diagnosed with localized cervical
cancer.
DISCUSSION
Overall Cancer Incidence and Mortality Trends in the U.S.
The overall decline in cancer death rates, which was
noted first in the 1990s, has accelerated in recent
years. Declines in colorectal cancer mortality in men
and women, especially recent declines from 2002
through 2004, together with the continuation of
long-term declines in mortality from lung and pros-
tate cancer in men and from breast cancer in
women, strongly contribute to the overall declining
cancer death rates.
Noteworthy in this year’s report are the decline
in the incidence of colorectal cancer in men and
women, the decline in breast cancer incidence in
women from 2001 through 2004, and a leveling of
lung cancer incidence in women after long-term
increases. Lung cancer incidence rates in men con-
tinue to decline, and the prostate cancer trend was
level.TA
B
LE
6
(c
on
ti
nu
ed
)
C
ha
ra
ct
er
is
ti
cs
U
.S
.N
H
W
U
.S
.A
I/
AN
AI
/A
N
by
In
di
an
he
al
th
se
rv
ic
e
(I
H
S)
re
gi
on
N
or
th
er
n
pl
ai
ns
Al
as
ka
So
ut
he
rn
pl
ai
ns
Pa
ci
fic
co
as
t
Ea
st
So
ut
hw
es
t
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
Pa
p
te
st
in
w
om
en
(a
ge
d
18
ye
ar
s
an
d
ol
de
r)
e
w
ith
in
th
e
pa
st
3
ye
ar
s
86
.4
(8
6.
2–
86
.6
)
82
.4
(8
0.
1–
84
.5
)
84
.4
(7
9.
9–
88
.0
)
92
.7
(8
9.
4–
95
.1
)
80
.4
(7
5.
5–
84
.6
)
83
.4
(7
6.
4–
88
.7
)
80
.9
(7
6.
5–
84
.6
)
82
.1
(7
6.
9–
86
.2
)
PS
A
te
st
in
m
en
(a
ge
d
50
ye
ar
s
an
d
ol
de
r)
w
ith
in
1
ye
ar
g
57
.9
(5
7.
4–
58
.4
)
49
.1
(4
3.
0–
55
.1
)
44
.5
(3
4.
3–
55
.1
)
34
.5
(2
4.
8–
45
.7
)
63
.7
(5
2.
2–
73
.9
)
44
.7
(2
5.
2–
66
.0
)
50
.1
(4
2.
1–
58
.0
)
38
.2
(2
8.
2–
49
.4
)
AI
/A
N
in
di
ca
te
s
Am
er
ic
an
In
di
an
/A
la
sk
a
N
at
iv
e;
N
H
W
,n
on
-H
is
pa
ni
c
w
hi
te
;9
5%
CI
,9
5%
co
nf
id
en
ce
in
te
rv
al
;P
ap
,P
ap
an
ic
ol
ao
u;
PS
A,
pr
os
ta
te
-s
pe
ci
fic
an
tig
en
.
a
So
ur
ce
:T
ab
le
s
P1
48
C,
P1
48
I,
P1
59
C,
P1
59
I
fr
om
th
e
Ce
ns
us
20
00
Su
m
m
ar
y
Fi
le
3
(S
F
3)
pr
ep
ar
ed
by
th
e
U
.S
.C
en
su
s
Bu
re
au
,2
00
2.
b
So
ur
ce
:B
eh
av
io
ra
lR
is
k
Fa
ct
or
Su
rv
ei
lla
nc
e
Sy
st
em
(B
RF
SS
),
19
99
–2
00
2,
20
04
,a
nd
20
05
.
c
So
ur
ce
:B
RF
SS
,2
00
1,
20
02
,2
00
4,
an
d
20
05
;o
be
si
ty
is
ba
se
d
on
bo
dy
m
as
s
in
de
x
>
30
kg
/m
2
an
d
<
99
.8
kg
/m
2 .
d
So
ur
ce
:B
RF
SS
,2
00
1,
20
02
,2
00
4,
an
d
20
05
.
e
So
ur
ce
:B
RF
SS
,1
99
9,
20
00
,2
00
2,
an
d
20
04
.
f
So
ur
ce
:B
RF
SS
,1
99
9,
20
01
,2
00
2,
an
d
20
04
.E
nd
os
co
py
in
cl
ud
es
si
gm
oi
do
sc
op
y
an
d
co
lo
no
sc
op
y.
g
So
ur
ce
:B
RF
SS
,2
00
1
an
d
20
02
.

D
at
a
su
pp
re
ss
ed
be
ca
us
e
of
sm
al
ln
um
be
rs
of
<
50
pe
rs
on
s.
Report to the Nation, 19752004/Espey et al. 2135
TABLE 7
Incidence Rates and Rate Ratios of the Top 15 Cancers for American Indian/Alaska Native Males Compared With Non-Hispanic White Males
by Indian Health Service Region, Contract Health Service Delivery Area Counties in Selected Areas in the United States, 1999–2004
Cancer site or typea
U.S. (CHSDA counties) Northern plains Alaska
AI/AN
NHW ratec
AI/AN:NHW AI/AN
NHW ratec
AI/AN:NHW AI/AN
NHW ratec
AI/AN:NHW
Rank Ratec RR 95% CI Rank Ratec RR 95% CI Rank Ratec RR 95% CI
All sitesb 406.9 553.5 0.74d 0.72–0.75 611.4 542.5 1.13d 1.06–1.20 543.3 569.0 0.95 0.88–1.03
Prostate 1 104.0 154.7 0.67d 0.64–0.70 1 164.6 160.0 1.03 0.91–1.16 3 82.1 179.9 0.46d 0.37–0.56
Lung and bronchus 2 68.0 87.6 0.78d 0.73–0.82 2 115.5 86.7 1.33d 1.15–1.54 1 116.5 84.8 1.37d 1.14–1.64
Colon and rectum 3 51.5 60.4 0.85d 0.80–0.91 3 79.8 62.0 1.29d 1.08–1.52 2 98.5 61.4 1.60d 1.31–1.95
Kidney and renal pelvis 4 22.7 17.4 1.31d 1.20–1.43 4 29.7 17.4 1.71d 1.33–2.15 5 28.6 18.7 1.53d 1.06–2.16
Urinary bladder 5 16.1 41.5 0.39d 0.34–0.43 5 27.6 39.4 0.70d 0.49–0.95 6 23.0 47.3 0.49d 0.31–0.71
Non-Hodgkin lymphoma 6 14.9 23.2 0.64d 0.57–0.72 8 20.2 22.8 0.89 0.61–1.24 11 13.2 26.3 0.50d 0.32–0.76
Stomach 7 14.2 8.5 1.67d 1.48–1.88 9 16.7 8.4 1.98d 1.33–2.80 4 34.6 7.7 4.46d 2.89–6.84
Oral cavity and pharynx 8 13.0 16.6 0.78d 0.70–0.88 6 21.5 15.3 1.40 0.98–1.92 8 20.9 15.3 1.36 0.92–1.97
Liver and IBD 9 13.0 6.4 2.02d 1.79–2.27 7 21.0 5.4 3.89d 2.71–5.37 9 17.2 8.2 2.09d 1.19–3.46
Leukemia 10 10.6 16.4 0.65d 0.57–0.73 11 13.7 16.4 0.84 0.58–1.17 12 8.4 15.2 0.55d 0.31–0.95
Pancreas 11 9.7 12.6 0.77d 0.66–0.88 13 9.9 12.0 0.82 0.50–1.26 7 21.4 9.6 2.22d 1.37–3.47
Esophagus 12 7.8 8.7 0.90 0.76–1.05 10 14.1 9.3 1.52 0.95–2.28 10 13.2 9.3 1.43 0.80–2.39
Myeloma 13 6.5 6.3 1.03 0.86–1.22 14 7.1 6.5 1.10 0.60–1.82   6.1  
Melanoma of the skin 14 5.9 27.4 0.21d 0.18–0.25   19.0     16.4  
Larynx 15 5.3 6.7 0.78d 0.64–0.94 12 10.3 6.5 1.58 0.88–2.56   5.2  
Brain and ONS 16 5.0 8.7 0.57d 0.48–0.67 15 5.6 8.4 0.66 0.37–1.11   8.1  
Testis 17 4.0 6.6 0.61d 0.52–0.71 17 5.1 6.5 0.79 0.51–1.24 13 6.1 7.1 0.86 0.50–1.48
Gallbladder 18 2.5 0.7 3.70d 2.65–4.99   0.6       
Cancer site or typea
Southern plains Pacific coast East
AI/AN
NHW ratec
AI/AN:NHW AI/AN
NHW ratec
AI/AN:NHW AI/AN
NHW ratec
AI/AN:NHW
Rank Ratec RR 95% CI Rank Ratec RR 95% CI Rank Ratec RR 95% CI
All sitesb 568.2 549.3 1.03 1.00–1.07 333.0 556.8 0.60d 0.57–0.63 286.3 578.4 0.50d 0.44–0.55
Prostate 1 156.9 146.6 1.07 0.99–1.15 1 83.1 160.4 0.52d 0.47–0.57 1 82.9 156.3 0.53d 0.43–0.65
Lung and bronchus 2 108.7 109.1 1.00 0.91–1.09 2 56.5 82.4 0.69d 0.60–0.78 2 45.4 94.5 0.48d 0.36–0.63
Colon and rectum 3 68.9 63.5 1.08 0.97–1.21 3 44.0 56.4 0.78d 0.67–0.90 3 35.5 65.9 0.54d 0.38–0.73
Kidney and renal pelvis 4 25.2 17.8 1.41d 1.19–1.67 4 14.8 16.8 0.88 0.70–1.10 5 15.1 18.7 0.81 0.48–1.27
Urinary bladder 5 24.8 34.9 0.71d 0.58–0.85 5 13.3 41.9 0.32d 0.24–0.41 4 20.4 43.9 0.46d 0.28–0.70
Non-Hodgkin lymphoma 6 23.5 22.1 1.06 0.87–1.28 8 12.6 24.1 0.52d 0.40–0.67   23.9  
Stomach 12 10.2 7.3 1.40d 1.05–1.83 9 11.8 8.2 1.43d 1.05–1.90   9.9  
Oral cavity and pharynx 7 18.5 18.3 1.01 0.82–1.23 7 12.6 17.1 0.74d 0.58–0.93 6 9.8 16.8 0.58d 0.33–0.96
Liver and IBD 11 11.1 6.1 1.81d 1.37–2.34 6 12.7 6.5 1.94d 1.50–2.46   6.9  
Leukemia 8 17.2 16.3 1.06 0.85–1.30 10 9.3 16.6 0.56d 0.41–0.74   17.1  
Pancreas 9 12.3 13.0 0.95 0.72–1.22 12 6.6 12.8 0.52d 0.35–0.73   13.3  
Esophagus 14 8.5 7.8 1.10 0.78–1.49 11 7.5 8.7 0.86 0.60–1.18   8.8  
Myeloma 15 8.3 5.8 1.41d 1.01–1.92 14 4.6 6.4 0.72 0.45–1.08   6.5  
Melanoma of the skin 10 11.6 20.4 0.57d 0.44–0.73 13 5.6 31.9 0.18d 0.12–0.26   27.2  
Larynx 13 9.1 7.8 1.17 0.86–1.55 17 3.2 5.8 0.56d 0.33–0.88   8.2  
Brain and ONS 16 8.1 8.8 0.92 0.68–1.21 16 3.7 9.2 0.40d 0.26–0.60   8.6  
Testis 17 3.5 5.6 0.63d 0.43–0.91 15 3.8 7.2 0.53d 0.38–0.72   6.2  
Gallbladder   0.7     0.6     0.8  
Cancer site or type
a
Southwest
AI/AN AI/AN:NHW
Rank Ratec NHW ratec RR 95% CI
All sitesb 261.5 513.1 0.51d 0.49–0.54
Prostate 1 67.0 136.7 0.49d 0.44–0.54
Lung and bronchus 4 22.1 78.1 0.28d 0.24–0.34
Colon and rectum 2 26.7 56.1 0.48d 0.41–0.55
Kidney and renal pelvis 3 25.1 15.8 1.59d 1.35–1.85
Urinary bladder 11 5.5 41.1 0.13d 0.09–0.19
Non-Hodgkin lymphoma 7 10.4 20.5 0.51d 0.40–0.64
(continued)
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After steadily decreasing for many years, the
decline in colorectal cancer death rates has acceler-
ated. The concurrent declines in colorectal cancer
mortality and incidence are likely associated with
preventing colorectal cancer through screening and
removal of precancerous polyps, improving cancer
outcomes by earlier stage diagnosis, reducing exposure
to risk factors, and improving cancer treatment.46–52
Lung cancer incidence trends have stabilized for
women and have continued declining for men. Both
joinpoint and fixed-interval trends for lung cancer
death rates in women demonstrated a considerably
slower rate of increase (APC, 0.2%) from 1995
through 2004 than in earlier periods; lung cancer
incidence rates remained essentially unchanged from
1998 through 2004. The data suggest that the epi-
demic of tobacco-related lung cancer in women has
reached a plateau and likely will begin to decline,
similar to what is occurring in men, although some
fluctuations still may occur as trends stabilize.8,9,53,54
Prostate cancer incidence rates remained stable
over the past decade. However, substantial declines
in prostate cancer death rates occurred in all racial/
ethnic populations, a phenomenon previously ob-
served in the U.S.55 and in other western coun-
tries.56,57 The reasons for the decline in prostate
cancer mortality are unclear. PSA has been used widely
for prostate cancer screening,58 although to our knowl-
edge its efficacy in reducing prostate cancer mortality
has not been established,59 and its contribution to
declining mortality is uncertain.60,61 Other factors pos-
sibly related to declining prostate cancer mortality
rates include more effective treatment62–65 and serendi-
pitous effects of noncancer-directed therapies.66
The decrease in breast cancer incidence rates
from 2001 through 2004 is a change from increasing
rates during the previous 20 years. Although many
factors influence breast cancer incidence rates,
recent reports highlight changes in hormone-replace-
ment therapy (HRT) and screening mammography
use.67–71 Between the years 1987 and 2000, the per-
centage of women aged 40 years reporting a mam-
mogram within the past 2 years increased from
29.1% to 70.1%.72 Recently, however, the direction of
the trend with the percentage of women who had a
mammogram in the past 2 years reversed and
declined nearly 4 percentage points to 66.4%. Reduc-
tions in mammography use were observed in popu-
lations that previously reported higher rates: women
ages 50 to 64 years, NHW women, and women with
TABLE 7
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Cancer site or typea
Southwest
AI/AN
NHW ratec
AI/AN:NHW
Rank Ratec RR 95% CI
Stomach 5 16.0 7.2 2.23d 1.79–2.74
Oral cavity and pharynx 12 4.8 15.5 0.31d 0.21–0.43
Liver and IBD 6 12.6 6.2 2.05d 1.62–2.56
Leukemia 10 6.7 14.8 0.45d 0.34–0.59
Pancreas 8 7.6 11.5 0.66d 0.48–0.87
Esophagus 13 4.4 8.0 0.55d 0.36–0.79
Myeloma 9 7.4 5.4 1.37 0.98–1.84
Melanoma of the skin 17 3.6 29.5 0.12d 0.08–0.18
Larynx   6.1  
Brain and ONS 16 3.8 8.0 0.48d 0.32–0.68
Testis 14 4.2 6.3 0.67d 0.50–0.89
Gallbladder 15 4.1 0.7 6.33d 3.87–9.81
Source: Surveillance, Epidemiology, and Ends Results and National Program of Cancer Registries areas are reported by the North American Association of Central Cancer Registries as meeting high-quality data
standards from 1999 through 2004.
CHSDA indicates Indian Health Service (IHS) Contract Health Service Delivery Area; AI/AN, American Indian/Alaska Native; NHW, non-Hispanic white; RR, rate ratio; 95% CI, 95% confidence interval; IBD, intra-
hepatic bile duct; ONS, other nervous system.
a Cancers are sorted in descending order according to sex-specific rates for AI/AN. Greater than 15 cancers may appear to include the top 15 cancers in every IHS region.
b All sites excludes myelodysplastic syndromes and borderline tumors.
c Rates are per 100,000 persons and were age-adjusted to the 2000 U.S. standard population (19 age groups, Census p25–1130).
d The RR was statistically significant (P < .05).
 Statistic could not be calculated when <16 cases were reported.
Years of data and registries used (30 states). 1999–2004: Alabama, Alaska, California, Colorado, Connecticut, Florida, Idaho, Indiana, Iowa, Louisiana, Maine, Massachusetts, Montana, Nebraska, Nevada, New
Mexico, New York, North Dakota, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Washington, Wyoming; 1993–2003: Arizona, Wisconsin; 2000–2004: Michigan.
Percent regional coverage of AI/AN CHSDA data to all AI/AN in region: Alaska, 100%; East, 12.2%; North Plains, 38.1%; Pacific Coast, 55.1%; South Plains, 65%; Southwest, 86.1%.
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TABLE 8
Incidence Rates and Rate Ratios of the Top 15 Cancers for American Indian/Alaska Native Females Compared With Non-Hispanic White Females
by Indian Health Service Region, Contract Health Service Delivery Area Counties in Selected Areas in the United States, 1999–2004
Cancer site or typea
U.S. (CHSDA counties) Northern plains Alaska
AI/AN
NHW ratec
AI/AN:NHW AI/AN
NHW ratec
AI/AN:NHW AI/AN
NHW ratec
AI/AN:NHW
Rank Ratec RR 95% CI Rank Ratec RR 95% CI Rank Ratec RR 95% CI
All sitesb 334.8 425.8 0.79d 0.77–0.80 468.1 413.3 1.13d 1.07–1.20 511.0 415.3 1.23d 1.15–1.32
Breast 1 84.7 134.8 0.63d 0.60–0.65 1 112.2 130.5 0.86d 0.77–0.96 1 139.5 135.6 1.03 0.91–1.17
Lung and bronchus 2 48.0 59.2 0.81d 0.77–0.86 2 97.4 52.0 1.87d 1.64–2.12 3 78.9 59.9 1.32d 1.08–1.59
Colon and rectum 3 41.6 43.8 0.95 0.90–1.01 3 60.4 45.3 1.33d 1.13–1.57 2 106.2 40.6 2.62d 2.18–3.14
Corpus and uterus, NOS 4 18.2 23.4 0.78d 0.71–0.84 4 21.3 26.7 0.80 0.60–1.03 5 14.0 22.9 0.61d 0.41–0.90
Kidney and renal pelvis 5 13.9 8.7 1.59d 1.44–1.75 5 18.8 9.3 2.03d 1.51–2.67 8 12.0 8.6 1.39 0.85–2.21
Non-Hodgkin lymphoma 6 12.8 16.4 0.78d 0.70–0.87 6 16.2 16.7 0.97 0.69–1.31 10 9.9 17.8 0.55d 0.33–0.88
Ovaryb 7 11.7 14.4 0.81d 0.73–0.90 7 12.6 14.0 0.90 0.63–1.25 12 7.6 13.5 0.56d 0.31–0.95
Pancreas 8 9.4 9.5 1.00 0.88–1.13 11 9.9 9.0 1.09 0.70–1.61 9 11.9 10.7 1.12 0.67–1.78
Cervix uteri 9 9.4 7.5 1.25d 1.11–1.39 9 11.3 7.5 1.50d 1.07–2.06 11 9.2 6.0 1.52 0.88–2.51
Thyroid 10 8.4 12.0 0.70d 0.63–0.79 10 10.2 11.9 0.86 0.60–1.19 6 12.6 12.3 1.03 0.69–1.50
Leukemia 11 7.8 9.7 0.80d 0.70–0.91 8 11.5 10.1 1.14 0.75–1.66 14 5.7 10.9 0.52d 0.27–0.92
Stomach 12 7.6 3.7 2.05d 1.77–2.35 14 7.4 3.5 2.12d 1.28–3.28 4 17.7 3.0 5.90d 3.41–10.38
Liver and IBD 13 5.9 2.5 2.39d 2.02–2.80 13 7.7 2.3 3.39d 1.97–5.35   2.7  
Myeloma 14 5.8 3.8 1.53d 1.30–1.79 15 5.6 4.0 1.41 0.80–2.28 13 7.5 4.0 1.88 0.95–3.55
Oral cavity and pharynx 15 4.9 6.4 0.77d 0.65–0.91 12 9.6 6.1 1.56d 1.03–2.26 7 12.3 5.8 2.12d 1.23–3.55
Urinary bladder 16 4.4 10.4 0.42d 0.35–0.50   10.5     8.6  
Melanoma of the skin 17 3.9 18.5 0.21d 0.18–0.25   13.7     12.7  
Gallbladder 18 3.8 1.1 3.36d 2.72–4.11   1.4       
Cancer site or typea
Southern plains Pacific coast East
AI/AN
NHW ratec
AI/AN:NHW AI/AN
NHW ratec
AI/AN:NHW AI/AN
NHW ratec
AI/AN:NHW
Rank Ratec RR 95% CI Rank Ratec RR 95% CI Rank Ratec RR 95% CI
All sitesb 439.2 403.7 1.09d 1.05–1.13 292.7 437.5 0.67d 0.64–0.70 258.3 435.1 0.59d 0.54–0.65
Breast 1 115.2 130.0 0.89d 0.83–0.95 1 74.5 142.5 0.52d 0.48–0.57 1 69.1 132.8 0.52d 0.43–0.62
Lung and bronchus 2 68.8 62.9 1.09 1.00–1.20 2 47.0 60.9 0.77d 0.68–0.87 2 45.2 61.3 0.74d 0.57–0.93
Colon and rectum 3 54.4 43.4 1.25d 1.13–1.39 3 34.8 42.0 0.83d 0.72–0.95 3 34.6 46.9 0.74d 0.56–0.96
Corpus and uterus, NOS 4 22.5 19.4 1.16 0.98–1.35 4 16.8 23.7 0.71d 0.59–0.85 4 13.1 24.4 0.54d 0.33–0.81
Kidney and renal pelvis 6 17.9 9.1 1.96d 1.62–2.36 7 10.4 8.3 1.26 0.98–1.59 5 11.5 9.2 1.25 0.77–1.91
Non-Hodgkin lymphoma 5 18.4 15.6 1.17 0.97–1.40 5 12.4 16.7 0.74d 0.58–0.93   16.8  
Ovaryb 7 14.4 14.0 1.03 0.84–1.25 8 9.9 14.9 0.66d 0.51–0.84   14.6  
Pancreas 9 9.9 8.7 1.13 0.87–1.44 6 10.8 9.7 1.12 0.85–1.43   10.0  
Cervix uteri 8 14.1 9.2 1.53d 1.25–1.86 10 6.9 7.0 0.98 0.74–1.27 6 8.2 7.7 1.07 0.62–1.71
Thyroid 11 9.3 8.1 1.14 0.89–1.44 11 6.3 11.0 0.57d 0.43–0.75 7 7.9 13.1 0.60d 0.34–0.98
Leukemia 10 9.7 9.7 1.00 0.78–1.26 9 7.5 9.7 0.77 0.57–1.02   9.8  
Stomach 13 7.4 3.4 2.18d 1.60–2.90 13 4.4 3.5 1.25 0.81–1.83   4.4  
Liver and IBD 17 5.3 2.8 1.88d 1.30–2.64 12 5.9 2.6 2.29d 1.58–3.18   2.4  
Myeloma 15 6.8 3.7 1.86d 1.36–2.50 15 4.1 3.8 1.09 0.70–1.60   4.0  
Oral cavity and pharynx 16 5.9 6.0 0.98 0.70–1.32 17 3.9 6.7 0.59d 0.39–0.84   6.5  
Urinary bladder 14 7.3 8.5 0.85 0.63–1.13 14 4.3 10.1 0.42d 0.27–0.62   11.3  
Melanoma of the skin 12 7.7 12.5 0.62d 0.47–0.80 16 4.0 22.5 0.18d 0.12–0.25   17.8  
Gallbladder 20 2.6 1.0 2.65d 1.53–4.31   1.1   1.1
Cancer site or type
a
Southwest
AI/AN
NHW ratec
AI/AN:NHW
Rank Ratec RR 95% CI
All sitesb 219.3 404.3 0.54d 0.52–0.57
Breast 1 50.4 127.2 0.40d 0.36–0.43
Lung and bronchus 6 10.3 56.9 0.18d 0.14–0.22
Colon and rectum 2 17.6 40.3 0.44d 0.37–0.51
Corpus and uterus, NOS 3 16.8 19.7 0.85d 0.73–0.99
Kidney and renal pelvis 5 12.6 8.2 1.54d 1.26–1.85
Non-Hodgkin lymphoma 7 9.0 14.9 0.60d 0.47–0.75
(continued)
2138 CANCER November 15, 2007 / Volume 110 / Number 10
high incomes and education levels.70 The drop in
incidence rates over the last several years may be
associated in part with the small but significant
decline in mammography use.68,70 A decrease in
breast cancer incidence attributable to lower mam-
mography use would represent an artifact of under-
diagnosis or delayed diagnosis and not a true
decrease in the rate of invasive breast cancer. Treat-
ment of ductal and lobular carcinomas in situ, most
of which are identified by screening mammography,
also may have contributed to the observed decrease
in breast cancer incidence.73
Recent reports also highlight the contribution
from the dramatic decrease in HRT among postmeno-
pausal women for the decrease in breast cancer inci-
dence rates, primarily in those ages 50 to 69 years, and
among women with estrogen receptor-positive
tumors, which are dependent on hormones for their
growth.69 Follow-up of women in the Women’s Health
Initiative may provide valuable answers to the impact
of HRT cessation on breast cancer risk or timing and
whether the impact can be sustained over time or
throughout a woman’s life. Whether the decline in inci-
dence will accelerate the existing mortality decline also
needs to be determined.
Because HRT is also a risk factor for ovarian can-
cer,74 the decline in breast cancer incidence rates
prompted further examination of recent trends in
ovarian cancer. Ovarian cancer incidence rates have
been declining since the mid-1980s. However, in this
study, the rate of decline among white women chan-
ged from 1.0% per year during 1995 through 2001
to 3.3% per year during 2001 through 2004. The
earlier declines in ovarian cancer incidence rates
have been attributed in part to oral contraceptive
use,75,76 whereas the most recent downturn, such as
that observed in breast cancer, may be related to the
abrupt reversal in HRT use.
The incidence of kidney cancer has been rising
among men and women since 1975, but death rates
have been declining since 1992. Similar incidence
patterns are observed in fixed-interval trends for
1995 through 2004 for most racial/ethnic popula-
tions. Much of the increase in incidence has been
attributed to small tumors77 or tumors diagnosed
unexpectedly in patients who undergo diagnostic
TABLE 8
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Cancer site or type
a
Southwest
AI/AN
NHW ratec
AI/AN:NHW
Rank Ratec RR 95% CI
Ovaryb 4 13.1 13.7 0.95 0.79–1.14
Pancreas 11 7.9 8.5 0.92 0.70–1.18
Cervix uteri 10 7.9 7.5 1.06 0.83–1.33
Thyroid 9 8.4 14.5 0.58d 0.47–0.71
Leukemia 14 6.1 9.4 0.65d 0.50–0.84
Stomach 8 8.8 3.1 2.84d 2.18–3.64
Liver and IBD 15 6.0 2.3 2.61d 1.89–3.51
Myeloma 13 6.1 3.0 2.01d 1.48–2.66
Oral cavity and pharynx 18 2.1 5.9 0.35d 0.21–0.54
Urinary bladder   10.1  
Melannoma of the skin 20 1.8 18.5 0.10d 0.06–0.15
Gallbladder 12 6.6 0.9 7.10d 5.08–9.68
Source: Surveillance, Epidemiology, and Ends Results and National Program of Cancer Registries areas are reported by the North American Association of Central Cancer Registries as meeting high-quality data
standards from 1999 through 2004.
CHSDA indicates Indian Health Service (IHS) Contract Health Service Delivery Area; AI/AN, American Indian/Alaska Native; NHW, non-Hispanic white; RR, rate ratio; 95% CI, 95% confidence interval; NOS, not
otherwise specified; IBD, intrahepatic bile duct.
a Cancers are sorted in descending order according to sex-specific rates for AI/AN. Greater than 15 cancers may appear to include the top 15 cancers in every IHS region.
b All sites excludes myelodysplastic syndromes and borderline tumors.
c Rates are per 100,000 persons and were age-adjusted to the 2000 U.S. standard population (19 age groups, Census p25–1130).
d The RR was statistically significant (P < .05).
 Statistic could not be calculated when <16 cases were reported.
Years of data and registries used (30 states), 1999–2004: Alabama, Alaska, California, Colorado, Connecticut, Florida, Idaho, Indiana, Iowa, Louisiana, Maine, Massachusetts, Montana, Nebraska, Nevada, New
Mexico, New York, North Dakota, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Washington, Wyoming; 1999–2003: Arizona, Wisconsin; 2000–2004: Michigan.
Percent regional coverage of AI/AN CHSDA data to all AI/AN in region: Alaska, 100%; East, 12.2%; North Plains, 38.1%; Pacific Coast, 55.1%; South Plains, 65%; Southwest, 86.1%.
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TABLE 9
Stage-specific Incidence Counts and Rates for Selected Cancer Sites and Age Groups for American Indian/Alaska Native and Non-Hispanic White
Populations by Indian Health Service Region, Contract Health Service Delivery Area Counties in Selected Areas in the United States, 2001–2004;
Males and Females Combined
Cancer sitea/stageb
U.S. (CHSDA counties) NHW U.S. (CHSDA counties) AI/AN Northern plains AI/AN
Count Ratec (95% CI) R% Count Ratec (95% CI) R% Count Ratec (95% CI) R%
Colon and rectum (aged 50 years and older)
All stages 67,699 167.8 (166.6–169.1) 100.0 1,058 144.4 (135.5–153.7) 100.0 163 227.4 (191.7–267.8) 100.0
Local 25,037 62.2 (61.4–63.0) 37.0 340 46.9 (41.9–52.4) 32.1 48 63.7 (45.9–86.2) 29.4
Regional/distant 36,272 90.1 (89.1–91.0) 53.6 619 83.1 (76.5–90.2) 58.5 98 136.5 (109.2–168.6) 60.1
Unknown 6,390 15.6 (15.2–16.0) 9.4 99 14.3 (11.6–17.6) 9.4 17 27.1 (15.3–44.3) 10.4
Breast (female aged 40 years and older)
All stages 95,866 294.5 (292.7–296.4) 100.0 1,370 184.5 (174.5–194.8) 100.0 189 254.5 (217.9–295.6) 100.0
Local 60,073 184.0 (182.5–185.4) 62.7 761 103.3 (95.9–111.1) 55.5 102 141.2 (114.1–172.9) 54.0
Regional/distant 30,524 95.4 (94.3–96.5) 31.8 505 66.7 (60.8–73.0) 36.9 75 95.8 (74.4–121.6) 39.7
Unknown 5,269 15.2 (14.7–15.6) 5.5 104 14.5 (11.7–17.7) 7.6    
Cervix uteri (aged 20 years and older)
All stages 4,729 10.2 (9.9–10.5) 100.0 175 12.1 (10.4–14.1) 100.0 19 13.0 (7.6–20.9) 100.0
Local 2,485 5.6 (5.4–5.8) 52.5 75 5.0 (3.9–6.3) 42.9    
Regional/distant 1,802 3.7 (3.5–3.9) 38.1 84 5.8 (4.6–7.2) 48.0    
Unknown 442 0.9 (0.8–1.0) 9.3 16 1.3 (0.7–2.2) 9.1    
Prostate (aged 50 years and older)
All stages 98,770 552.7 (549.3–556.2) 100.0 1,165 364.0 (342.1–387.1) 100.0 155 520.9 (433.7–620.6) 100.0
Local 75,737 421.2 (418.2–424.2) 76.7 811 243.5 (226.1–261.9) 69.6 106 325.5 (261.5–401.1) 68.4
Regional/distant 13,357 74.0 (72.7–75.2) 13.5 200 60.4 (51.8–70.1) 17.2 29 94.9 (61.1–141.2) 18.7
Unknown 9,676 57.6 (56.4–58.7) 9.8 154 60.1 (50.4–71.0) 13.2 20 100.6 (58.0–159.6) 12.9
Cancer site
a/stageb
Alaska AI/AN Southern plains AI/AN Pacific coast AI/AN
Count Ratec (95% CI) R% Count Ratec (95% CI) R% Count Ratec (95% CI) R%
Colon and rectum (aged 50 years and older)
All stages 153 321.5 (270.4–379.3) 100.0 333 191.4 (171.0–213.6) 100.0 211 129.7 (111.7–149.7) 100.0
Local 64 136.7 (104.0–176.3) 41.8 100 57.9 (46.9–70.7) 30.0 75 47.1 (36.4–59.9) 35.5
Regional/distant 82 172.0 (135.1–215.6) 53.6 194 109.4 (94.2–126.2) 58.3 123 74.5 (61.1–89.9) 58.3
Unknown     39 24.2 (17.0–33.2) 11.7    
Breast (female aged 40 years and older)
All stages 157 319.0 (269.6–375.1) 100.0 435 257.8 (233.9–283.4) 100.0 290 171.9 (151.5–194.3) 100.0
Local 89 188.2 (149.8–233.5) 56.7 247 145.3 (127.6–164.8) 56.8 164 99.3 (83.8–116.8) 56.6
Regional/distant 40 74.6 (52.9–102.9) 25.5 154 91.2 (77.3–107.0) 35.4 117 56.5 (54.3–80.7) 40.3
Unknown 28 56.2 (37.0–82.2) 17.8 34 21.3 (14.7–29.8) 7.8    
Cervix uteri (aged 20 years and older)
All stages     66 21.7 (16.7–27.6) 100.0 27 7.7 (5.0–11.5) 100.0
Local     33 10.7 (7.3–15.0) 50.0    
Regional/distant     29 9.7 (6.5–13.9) 43.9 17 4.8 (2.7–8.0) 63.0
Unknown            
Prostate (aged 50 years and older)
All stages 72 331.5 (249.8–431.0) 100.0 434 563.0 (508.5–621.7) 100.0 221 303.7 (261.6–350.7) 100.0
Local 53 235.6 (169.9–318.7) 73.6 318 399.7 (354.9–448.6) 73.3 156 210.9 (176.6–249.9) 70.6
Regional/distant     57 73.3 (54.7–96.3) 13.1 46 57.3 (40.4–79.0) 20.8
Unknown     59 90.0 (67.2–117.7) 13.6 19 35.5 (20.5–56.5) 8.6
Cancer site
a
/stage
b
East AI/AN Southwest AI/AN
Count Ratec (95% CI) R% Count Ratec (95% CI) R%
Colon and rectum (aged 50 years and older)
All stages 45 116.6 (84.1–157.4) 100.0 153 62.4 (52.6–73.5) 100.0
Local     42 17.3 (12.3–23.6) 27.5
Regional/distant 26 68.4 (44.1–101.0) 57.8 96 38.3 (30.8–47.1) 62.7
Unknown        
Breast (female aged 40 years and older)
All stages 61 154.8 (117.1–200.6) 100.0 238 97.7 (85.4–111.4) 100.0
Local 35 92.0 (63.2–129.2) 57.4 124 50.9 (42.1–60.9) 52.1
Regional/distant 23 56.9 (35.3–86.7) 37.7 96 39.8 (32.0–48.9) 40.3
Unknown     18 7.1 (4.1–11.4) 7.6
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evaluation for unrelated conditions.78 Trends from
SEER from 1997 through 2004 show that increases
over the past decade are confined to disease in a
localized stage.20
Long-term increases in incidence rates of NHL
continue in women but currently are stable in men,
and death rates have declined in recent years for
both men and women. Incidence trends for NHL
vary by histologic subtype, sex, race/ethnicity, and
age; long-term trends have been influenced, but are
not fully explained, by trends in human immunodefi-
ciency virus-related subtypes.79,80 Moreover, changes
in coding and classification complicate the analysis
of incidence trends by histologic subtype.81,82 Recent
mortality trends may be influenced by improving
survival; 5-year relative survival increased from
53.6% for cases diagnosed from 1993 through 1995 to
63.8% for cases diagnosed in 1996 through 2003.55
The rapid increase in thyroid cancer incidence rates
described in the 2006 annual report continued between
2003 and 2004 across all populations.9 It is postulated
that increases in the detection of small tumors related to
increased use of ultrasound and fine-needle aspiration
account for a large part of this increase.83
The increase in melanoma incidence trends has
slowed over the years, especially among men, in
whom the rates stabilized from 2000 through 2004.
The increase in the fixed-interval trends (1995
through 2004) of approximately 3% per year among
both men and women was also smaller than the 5%
increase per year during the mid-1970s to the mid-
1980s. Although long-term increases in melanoma
incidence rates are influenced by early detection and
improved reporting of cases diagnosed outside hospi-
tals, increasing trends are not confined to early-stage
tumors and also may be influenced by changes in
sun exposure.84
Increases in liver cancer incidence and mortality in
the U.S. population also have been noted previously.
The risk of liver cancer is elevated in persons with cir-
rhosis and chronic liver disease, and in the U.S., the
main preventable causes of these conditions are chronic
infection with hepatitis B and C viruses, chronic alcohol
abuse, and nonalcoholic fatty liver disease.85,86 In many
developing countries in which hepatitis B is endemic,
chronic hepatitis B virus infection is the major causal
agent,87 and it is likely that elevated liver cancer rates for
API and Hispanic men and women are related to high
rates of chronic viral hepatitis infection acquired in the
countries of origin of recent immigrants.88 Obesity and
Type 2 diabetes mellitus (Type 2 diabetes) also are emer-
ging as risk factors.86
Cancer in American Indians and Alaska Natives
The current report enhances AI/AN cancer surveil-
lance by presenting U.S. regional cancer incidence
rates and by addressing the significant race misclas-
sification of this population in cancer statistics. Link-
TABLE 9
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Cancer site
a
/stage
b
East AI/AN Southwest AI/AN
Count Ratec (95% CI) R% Count Ratec (95% CI) R%
Cervix uteri (aged 20 years and older)
All stages     50 11.2 (8.2–15.0) 100.0
Local     22 4.6 (2.8–7.0) 44.0
Regional/distant     22 4.9 (3.1–7.5) 44.0
Unknown        
Prostate (aged 50 years and older)
All stages 50 270.2 (196.0–363.6) 100.0 233 238.1 (207.2–272.3) 100.0
Local 34 172.5 (116.4–247.3) 68.0 144 141.8 (118.7–168.1) 61.8
Regional/distant     54 52.9 (39.1–69.9) 23.2
Unknown     35 43.4 (29.8–60.8) 15.0
Source: Surveillance, Epidemiology, and Ends Results (SEER) and National Program of Cancer Registries areas are reported by the North American Association of Central Cancer Registries as meeting high-quality
data standards for the specified years.
CHSDA indicates Indian Health Service (IHS) Contract Health Service Delivery Area; AI/AN, American Indian/Alaska Native; NHW, non-Hispanic white; 95% CI, 95% confidence interval; R%, percent distribution
of the stage-specific incidence rate.
a
Cancers were chosen based on existing evidence base for early detection.
b 2000 SEER Summary Stage was used for stage of disease at diagnosis.
c Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups, Census p25–1130).
 Statistic could not be calculated when <16 cases were reported.
Years of data and registries used (30 states), 2001—2003: Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Idaho, Indiana, Iowa, Louisiana, Maine, Massachusetts, Michigan, Montana,
Nebraska, Nevada, New Mexico, New York, North Dakota, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Washington, Wisconsin, and Wyoming.
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ing IHS and cancer registry data and restricting anal-
yses to CHSDA counties reduces AI/AN misclassifica-
tion and improves on the accuracy of cancer
incidence data previously reported for AI/AN. The
report also includes data from 30 state cancer regis-
tries and is more representative nationally of the AI/
AN population than previous reports.
Findings from this study, as well as prior reports
from specific regions or registries26,89–92 or from mor-
tality data,32,34 indicate that wide regional variation
is characteristic of AI/AN cancer surveillance and
that region-specific data are essential to characterize
the AI/AN cancer burden. In general, cancer rates
among AI/AN persons were highest in Alaska and the
Northern and Southern Plains and lowest in the
Southwest. The wide regional variations in cancer
rates may reflect in part geographic variations in
screening and in risk factors, such as tobacco use
(lung, kidney, and colorectal cancer), obesity (color-
ectal and breast cancer), low level of physical activity
(breast and colorectal cancer), heavy alcohol con-
sumption (breast and liver cancer), and dietary fac-
tors, including consumption of large amounts of red
meat and inadequate intake of fruits and vegetables
(colorectal cancer). Research designed to elucidate
regional variations in risk factors may help identify
appropriate prevention and control strategies.
The regional patterns of lung cancer rates mirror
the regional smoking prevalence from BRFSS, as
noted in this report and elsewhere.35 Although smok-
ing prevalence in AI/AN respondents in the South-
west is similar to that of NHW respondents, AI/AN
smokers in the Southwest tend to smoke fewer cigar-
ettes per day compared with non-AI/AN smokers
and AI/AN smokers in other regions.93,94 Predictably,
lung cancer incidence rates for the AI/AN population
in the Southwest were lower than the rates among
for the NHW population during the period of this
report, a pattern that was documented previously95,96
and that reflects the lower rate of cigarette consump-
tion.93,97,98 Nonetheless, radon exposure during ura-
nium mining caused a disproportionate number of
lung cancer cases among AI/AN men in this region
in the 1970s and 1980s99,100; the proportion of lung
cancer cases attributable to uranium-related expo-
sure in the past decade currently is unknown but
remains a concern in this region.
Smoking also has been associated with an
increased risk of developing101 or dying102 from col-
orectal cancer and of being diagnosed at an earlier
age.103 Furthermore, there is mounting evidence of
an association between Type 2 diabetes and colorec-
tal cancer,104,105 including a positive interaction of
smoking on this risk.106 The prevalence of Type 2 di-
abetes is generally higher in AI/AN persons, is grow-
ing rapidly,107 and exhibits regional differences35,108;
it is high in the Northern Plains and the Southwest
and low in Alaska, where, although it is lower, the
prevalence is increasing at a rapid rate.109 Finally,
colorectal cancer screening prevalence is low in the
NHW population and is lower still in the AI/AN
population except for endoscopic screening preva-
lence in the East and Alaska, where rates for the AI/
AN populations are similar to those for the NHW
populations. The parity in endoscopic screening
between AI/AN and NHW persons in Alaska may
reflect efforts in that state to increase screening for
the AI/AN population110,111 and also may reflect con-
cerns that use of FOBT may yield false-positive
results in a population with high prevalence of Heli-
cobacter pylori (H. pylori) infection.112 This finding
also is consistent with the observation of a higher
probability of early-stage diagnosis for colorectal
cancer in that region from this report.
Breast cancer incidence rates in AI/AN women
were lower than for NHW women overall. Although
the rate for AI/AN women was similar to the rate for
NHW women in Alaska, it was nearly 3 times the rate
of AI/AN women in the Southwest. Similar variations
have been reported previously and may be because
of differences in reproductive or behavioral risk fac-
tors or variations in mammography rates.91 Data
regarding variations in reproductive characteristics
among AI/AN women by region are limited, however.
One study reported no differences in age at first birth
among women receiving mammograms in IHS or
tribal clinics in Alaska, where incidence rates are
relatively high, compared with similar women in Ari-
zona, where incidence rates are is low.113 Although it
has been postulated that the recent decline in breast
cancer incidence in the general population is
because of the decline in use of HRT, no data are
available on HRT use in AI/AN women. Higher rates
of mammography in Alaska may be associated with
higher breast cancer incidence rates.
AI/AN persons have higher rates of cancers of
the kidney and gallbladder than other populations.
In this report, rates for kidney cancer were generally
higher in AI/AN than NHW populations, especially in
the Northern and Southern Plains and the Southwest.
The recognized risk factors for kidney cancer—smok-
ing and obesity—account for 20% to 30% of renal cell
cancers in the U.S.114 Other potential risk factors
include hypertension and end-stage renal disease,115
the prevalence of which is 3 times greater in AI/AN
than NHW populations.116
Gallbladder cancer is elevated in AI/AN men and
women for all regions combined; however, the cur-
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rent report permits presentation of regional rates
only for the Southern Plains for women and the
Southwest for women and men. Elevated rates in the
AI/AN population may be related to a high preva-
lence of cholelithiasis,117,118 a strong risk factor for
gallbladder cancer, and obesity.119 Recent declines in
gallbladder cancer incidence rates in AI/AN popula-
tions in the Southwest most likely are because of
increasing use of laparoscopic cholecystectomy in
this region.120
Previous reports have documented high inci-
dence rates of stomach cancer among AI/AN popula-
tions in many areas96,121,122; and, in the current
report, incidence rates for stomach cancer among
AI/AN persons were consistently higher than those
for NHW persons in Alaska, the Northern and South-
ern Plains, and the Southwest. In recent years,
chronic infection with H. pylori has emerged as a key
factor in the development of gastric cancer 123 and
several studies have documented high prevalence of
H. pylori infection in Native communities.112,124
Tobacco smoking, alcohol abuse, and obesity—with a
higher prevalence among AI/AN than NHW popula-
tions—also are associated with an elevated risk of
stomach cancer, especially gastric cardia adenocarci-
noma.125–127 Additional research is needed to charac-
terize the combination of risk factors that place AI/
AN persons at higher risk of this disease.
Although liver cancer incidence is increasing in
most race/ethnic populations in the U.S., it was ele-
vated consistently in AI/AN men and women com-
pared with NHW men and women for the period
1999 through 2004. Alcohol-related morbidity varies
across AI/AN communities but remains a significant
health concern for many tribal groups.35,128,129 Before
the introduction of hepatitis B vaccination, chronic
hepatitis B virus infection was endemic among AI/
AN persons in Alaska.130 Alcohol abuse and viral
hepatitis have a synergistic, positive association with
liver cancer and are likely contributors. Furthermore,
in 2002, the proportion of deaths attributable to
chronic liver disease, a significant risk factor for liver
cancer, was 4 times greater in AI/AN populations
compared with U.S. white populations.131
Healthcare for American Indians and Alaska Natives
This study reports less favorable socioeconomic sta-
tus and healthcare access for AI/AN groups com-
pared with NHW groups. Having a usual source of
care is a key predictor of cancer screening and other
preventive services46; and consistent with this, the
cancer screening prevalence for AI/AN populations is
lower compared with the prevalence for NHW popu-
lations.
Previous studies have documented that AI/AN
populations have been diagnosed disproportionately
with late-stage disease and have relatively poor 5-year
survival compared with other populations.7,132–137
The findings in this report are consistent with previ-
ous studies, indicating that AI/AN populations may
not have benefited from available screening technol-
ogies and generally have more late-stage diagnoses
than NHW populations. These observations in AI/AN
populations have led to the development of cultu-
rally appropriate screening programs in many
regions.138–141 Although data are limited on factors
that may be associated with later stage at diagnosis
among AI/AN populations, studies in other racial
groups suggest that stage differences among popula-
tions may be influenced by awareness of cancer
symptoms, access to a regular healthcare provider,
and adequacy of follow-up for abnormal screening
results, including timeliness between the first
abnormal test result and receiving a definitive dia-
gnosis.142,143 Despite persistent disparities, remark-
able progress has been made in cervical cancer
control.144
The IHS provides primary healthcare to approxi-
mately 1.8 million enrolled members of federally
recognized tribes of the estimated 3.3 million AI/AN
in the U.S.145 The 150 IHS hospitals and clinics are
located primarily on reservation lands and in a few
cities with relatively large AI/AN populations. Half of
these healthcare facilities are managed by tribal gov-
ernments under negotiated agreements with the fed-
eral government, and half are operated directly by
the federal government. An additional 34 urban
health centers receive some federal funding to pro-
vide healthcare to urban AI/AN. Eligible AI/AN peo-
ple can receive free healthcare at any IHS facility, but
a complex set of rules governs and restricts delivery
of contract health services for specialty medical care,
such as cancer treatment, which generally is not
available in IHS facilities. AI/AN people who do not
live within the CHSDA counties, who do not have
access to an IHS facility, or who receive non-IHS
health benefits may not receive any health benefits
from IHS. Funding for IHS is by Congressional
appropriation and currently is at the level of $2532,
compared with $5645 per capita personal medical
services for U.S. citizens.146 Lower funding for IHS,
combined with remote rural residence, may contri-
bute to the lack of primary care even in the CHSDA
counties. Geographic, financial, and bureaucratic
barriers to receiving appropriate cancer treatment as
well as cultural beliefs also may contribute to poor
survival rates among AI/AN persons.
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Outreach and Community Programs for American
Indians and Alaska Natives
Cancer control only recently has become an impor-
tant concern for many AI/AN communities as cancer
surveillance has revealed substantial increases in
cancers that once were quite rare in this popula-
tion.147–150 Committed professionals, community lea-
ders, survivors, and partnering agencies have
initiated programs to promote comprehensive cancer
control in AI/AN communities. Although much
remains to be done, the CDC, NCI, ACS, and other
agencies have collaborated with the IHS and tribal
and state partners around the country to improve
cancer control for AI/AN populations by funding
screening and treatment services, supporting coali-
tions, building cancer control infrastructure, educat-
ing professionals and the public, and supporting
surveillance and research.
Although the IHS-initiated cervical cancer
screening in the 1960s and 1970s resulted in declin-
ing cervical cancer incidence and mortality rates in
the 1980s and 1990s,90,144 little screening mammog-
raphy was being provided to women served by the
IHS before the establishment of the CDC’s National
Breast and Cervical Cancer Early Detection Program.
Fourteen tribal programs, in addition to all 50 states,
currently receive support from this program to build
infrastructure and provide screening services (Arctic
Slope Native Association Limited, Barrow, Ark; Cher-
okee Nation, Tahlequah, Okla; Cheyenne River Sioux
Tribe, Eagle Butte, SD; Hopi Tribe, Kykotsmovi, Ariz;
Kaw Nation of Oklahoma, Newkirk, Okla; Mississippi
Band of Choctaw Indians, Choctaw, Miss; Native
American Rehabilitation Association of the North-
west, Portland, Ore; Navajo Nation, Window Rock,
Ariz; Poarch Band of Creek Indians, Atmore, Ala;
South East Alaska Regional Health Consortium, Sitka,
Alaska; South Puget Intertribal Planning Agency,
Shelton, Wash; Southcentral Foundation, Anchorage,
Alaska; and Yukon-Kuskokwim Health Corporation,
Bethel, Ark). Annual training for primary care provi-
ders to perform colposcopy, part of standard diag-
nostic follow-up for abnormal Pap smear results, is
provided by IHS and CDC to increase the number
and distribution of providers trained in colposcopy
and to reduce the time from abnormal screening
results to definitive diagnosis.151,152 Continued dili-
gence in education, training, and prevention services
to further reduce the death rate from cervical cancer
is essential.
The NCI Network for Cancer Control Research
Among AI/AN Populations (the Network) is a forum
for Native and non-Native researchers with a mission
to reduce preventable cancer morbidity and mortal-
ity to the lowest levels possible and to improve sur-
vival from cancer to the highest level possible in AI/
AN populations.153 Realizing the importance of AI/
AN community participation in research, the Net-
work also provides curriculum development and
instructors for an annual cancer control training
course for Native researchers.154 NCI is an important
partner in promoting and funding community net-
works programs, such as the ‘‘Spirit of Eagles’’ based
at the Mayo Clinic in Rochester, Minnesota. This
program works with major cancer centers, nonprofit
organizations, policy boards, professional societies,
and educators through community-based cancer
control grants.155 NCI has funded 3 other regional or
local community networks in the Pacific Northwest,
the Southwest, and Oklahoma. The NCI Cancer In-
formation Service collaborates with community net-
works to reach medically underserved audiences and
partners with researchers to develop messages, chan-
nels, and strategies for communicating risk and early
detection approaches for AI/AN populations. In addi-
tion, NCI has initiated the Patient Navigator Research
Program to reduce the time from an abnormal
screening, to a definitive diagnosis, and, finally, to
treatment.
IHS, CDC, NCI, ACS, NAACCR, and others work
to improve cancer data among AI/AN populations.
NCI gives technical assistance and training to tribes
and regional Indian Health Boards to establish and
maintain tribally operated cancer registration sys-
tems. Current projects are the Cherokee Nation Can-
cer Registry (Oklahoma), the Northwest Portland
Area Registry Project (Idaho, Oregon, and Washing-
ton),92,156 and the South Dakota Patterns of Care Pro-
ject. In addition, the Alaska Native Tumor Registry is
a part of the SEER Program. In most cases, the indi-
vidual tribal projects collaborate with state-operated
cancer registries through special agreements to
exchange information, maintain confidentiality, and
contribute to more complete and accurate informa-
tion concerning cancer in AI/AN communities.
Finally, the CDC provides epidemiologic support and
funding to the IHS to conduct the linkages for popu-
lation-based cancer registries and promotes other
cancer control activities that target AI/AN popula-
tions.
In the mid-1990s, CDC, ACS, and others pro-
moted the concept of comprehensive cancer control
to improve coordination of cancer control activities
in state and local health departments and tribal orga-
nizations.157 The CDC Comprehensive Cancer Con-
trol Program began in 1998 and, since then, it has
funded 6 tribal organizations (Alaska Native Tribal
Health Consortium, South Puget Intertribal Planning
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Agency, Northwest Portland Area Indian Health
Board, Aberdeen Tribal Chairmen’s Health Board,
Fond Du Lac Reservation, and Cherokee Nation) and
all 50 states, the District of Columbia, and several
U.S. territories. The National Partnership for Com-
prehensive Cancer Control, a group of national orga-
nizations that includes NAACCR, the Intercultural
Cancer Council, and C-Change, now promotes com-
prehensive cancer control at federal, state, local,
tribal, and territorial levels; they also support Com-
prehensive Cancer Control Leadership Institutes to
improve implementation of cancer plans in tribal
communities. Nonprofit organizations such as ACS
and the Lance Armstrong Foundation are providing
new resources to AI/AN cancer control efforts. The
ACS program Circle of Life is designed to decrease
the breast cancer incidence and death rates among
American Indian women. The Lance Armstrong
Foundation has developed a strategic plan for AI/AN
survivors to help overcome the fatalism that often
accompanies a diagnosis of cancer in the community
setting. All these efforts and more are essential to
reducing the burden of cancer in AI/AN populations.
Issues in Data Interpretation
The cancer surveillance infrastructure in the U.S.
now provides cancer incidence data for most of the
population by site, sex, race, and Hispanic origin.
However, several limitations in the data collection
and analyses may influence the interpretation of
results in this report.
First, the 2 methods that were used for trend
analysis—joinpoint and fixed-interval trends—some-
times appear to yield different results. The joinpoint
method is used for long-term trends but also has the
flexibility to identify changes in magnitude and
direction of the trend within shorter intervals. The
fixed-interval method facilitates comparison between
groups but lacks the flexibility to identify changes in
the trend over the fixed interval. Although they were
not presented, when joinpoint analyses were applied
to the fixed-interval time period, the results were
more comparable to the long-term trends despite the
differences in the U.S. population coverage of 59%
for the fixed-interval analyses and 10% for the long-
term joinpoint analyses and despite the lack of delay
adjustment in the fixed-interval approach.
Second, as discussed earlier, it was discovered
that many AI/AN persons were misclassified as
another race in cancer registry data, and the extent
of misclassification varied by registry, ranging from
36% in Minnesota to 57% in California in published
studies.21–24,158,159 Although linkage with the IHS
patient registration database improves the race clas-
sification for AI/AN cases, the issue is not resolved
completely, because AI/AN persons who are not
members of the federally recognized tribes and are
not eligible for IHS services are under-represented in
the IHS database. Because the denominators used in
the rate calculations were derived from the U.S. Cen-
sus estimates, which are based on self-identification
of race (because it is preferred as the most accurate
classification), the actual rates for AI/AN persons
may be higher than those reported in our study.
Third, the analyses presented here for AI/AN
populations are based on residents of CHSDA coun-
ties and exclude many AI/AN residents in urban
areas that are not included in the CHSDA counties;
therefore, the findings may not represent all AI/AN
populations in the U.S. or in individual IHS regions
(see Supplementary Table 1B; available at URL:
www.seer.cancer.gov/report_to_nation/). In particu-
lar, the East region includes only 12.2% of the total
AI/AN population in that region.
Fourth, the current analysis revealed less varia-
tion for NHW populations than for AI/AN popula-
tions by IHS regions using data from CHSDA
counties only. This approach may obscure variation
in cancer rates for NHW populations by alternate
state or county groupings.
Finally, the median BRFSS response rate is
approximately 50%, the response rates vary widely by
state, and the surveys rely exclusively on telephone
interviews.35 Telephone coverage also varies within
the AI/AN population and is lower in this population
compared with other racial/ethnic groups.35 Gener-
ally, the questions regarding cancer screening tests
do not distinguish between tests conducted for
screening and tests conducted for diagnostic pur-
poses. Mixed-mode sampling approaches (ie, com-
bining random digit dialing, computerized address
databases, web surveys, etc) are being investigated to
address concerns about nonresponse and the declin-
ing coverage of the population with traditional land-
line household phones.160
Future Directions
Each year, the annual report to the nation on cancer
brings together key agencies and organizations
engaged in cancer surveillance in the U.S. to describe
the latest cancer incidence and mortality data for the
general population and to focus on a topic that war-
rants special attention. This year’s report represents
the 10th anniversary of this collaboration and pro-
vides improved data for AI/AN, highlighting the re-
gional burden of cancer and the distinctive patterns
of specific cancers in this population.
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Cancer registrars rely on information available in
medical and administrative records for race/ethnicity
information; this information often is not available
or is not collected and recorded in a systematic man-
ner. Several recent reports have recommended that
hospitals implement a uniform framework for the
collection of data concerning race, ethnicity, and lan-
guage, including a rationale for reporting these data,
providing scripts and developing other tools to facili-
tate data collection.161 Another approach to improve
race classification further for AI/AN is the develop-
ment and expansion of tribal rosters, such as the
Northwest tribal roster,25 to complement the IHS
patient registration database and thereby increase
the usefulness of data linkages.
The high rate of misclassification of AI/AN race
on death certificates has been documented in several
studies.27,162 Although the cancer mortality data pre-
sented in this report were not linked to the IHS
patient registration database to address racial mis-
classification and likely are underestimates, the de-
velopment of linkage protocols for death certificates
is in progress for addressing this challenge in future
reports.
Improved surveillance data advance cancer con-
trol and guide future research to address gaps in
knowledge. The AI/AN population has high incidence
rates of several cancers for which some risk factors
are modifiable, such as cigarette smoking, alcohol
consumption, obesity, infectious agents (H. pylori
and several viruses—hepatitis B, hepatitis C, and
human papillomavirus), and possibly diabetes. To
reduce cancer burden in AI/AN populations, specific
cancer prevention and control interventions should
be targeted accordingly and tailored to their special
needs. In addition, the generally lower cancer screen-
ing rates for AI/AN provide a compelling case for
enhanced cancer screening programs for AI/AN
populations in all regions. Regional geographic varia-
tions for the AI/AN populations are important when
developing cancer control policies for these popula-
tions. AI/AN often live in remote communities with
limited access to prevention services and unfavorable
socioeconomic conditions, factors that further com-
plicate successful cancer control programs. Deliver-
ing cancer screening and other preventive services in
these communities hinges on innovative and cultu-
rally appropriate interventions. National and local
cancer control partners should work with tribes to
develop such demonstration projects and to explore
other research needs (eg, identifying causes of the
disproportionately high rates of colorectal cancer in
Alaska and the Northern Plains, examining the deter-
minants of low breast cancer rates in AI/AN women
in the Southwest, or evaluating the association of di-
abetes to patterns of colorectal and other cancers in
AI/AN populations).
Cigarette smoking remains the single most im-
portant behavioral risk factor for cancer. This is espe-
cially true for the AI/AN population, in which the
use of both cigarettes and smokeless tobacco are
substantially higher than in any other racial or ethnic
population in the U.S.163 Although American Indians
have cultivated and used tobacco since pre-Colum-
bian times, the recreational or habitual use of com-
mercial tobacco products is a relatively recent
phenomenon. Many AI/AN individuals still use
tobacco as part of traditional ceremonial or healing
practices, so tobacco cessation programs must adopt
culturally appropriate approaches. There are some
tobacco control activities under way, such as the
tribal tobacco centers funded by the CDC Office on
Smoking and Health and tobacco cessation clinics in
a few IHS and tribal clinics. These activities have
been rather limited, however; and, until this problem
is addressed with substantial resources, further
increases in the incidence of lung cancer and other
tobacco-related cancers can be expected in the AI/
AN population.
AI/AN populations must have improvements in
access to high-quality cancer treatment. Achieving
this will require changes in the healthcare delivery
system for AI/AN. Few IHS and tribal facilities have
specialized cancer care capabilities. Many AI/AN
patients must travel long distances at substantial
expense for clinic appointments or for scheduled
treatment. AI/AN patients who are unfamiliar with
the healthcare system are bewildered by the com-
plexity and confusion of specialty cancer care.
Expansion of initiatives such as the patient navigator
programs could greatly improve access of AI/AN
patients to needed preventive and treatment services.
This report emphasizes the importance of ana-
lyzing regional cancer incidence data for the AI/AN
population to interpret a national picture which, by
conveying overall lower AI/AN cancer incidence
rates, creates the impression that cancer is not a pri-
ority for the AI/AN population. In keeping with what
was noted in last year’s report regarding the Hispanic
population, subgroup analysis is essential to under-
stand those differences—by region in the case of the
AI/AN population—and to develop appropriate inter-
ventions. Information on geographic variation in
cancer rates for NHW, non-Hispanic black, and His-
panic populations is available widely through the
dissemination of state incidence and death rates in
such publications as the United States Cancer Statis-
tics, Cancer in North American from the NAACCR,
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Cancer Facts and Figures from the ACS, and the Can-
cer Planet website. Consideration should be given to
providing regional data for the AI/AN population
when state-based data are provided for other popula-
tions. Key to long-range improvement in cancer inci-
dence, morbidity, and mortality is building the
infrastructure to support comprehensive cancer con-
trol at the community level. The data in this report
will strengthen those efforts.
In conclusion, considerable progress has occurred
in cancer surveillance in AI/AN populations to pro-
vide a more comprehensive and accurate picture of
the cancer burden in this population than was avail-
able previously. This report describes disparities in
cancer incidence and gaps in cancer risk factors and
screening that provide a clear, albeit challenging,
course of action for national and local cancer control
partners. Sufficient diagnostic and treatment capacity
must be made available as screening services expand
to accommodate those persons with positive screen-
ing examinations or those who are diagnosed with
cancer. The substantial strides made in cervical can-
cer control for AI/AN women over the last 20 years
by expanding screening and diagnostic follow-up ser-
vices should serve as a model for addressing other
cancers and risk factors. Future progress in decreas-
ing the cancer burden in AI/AN populations is neces-
sary and achievable with implementation of
comprehensive cancer control programs that provide
direction and motivate and actively engage partners
across the spectrum of cancer control advocates,
healthcare providers, policymakers, tribal leaders,
and funding agencies.
In summary, the collaboration among the major
public health cancer surveillance organizations in
the U.S. (including, for the first time this year, the
IHS) to produce the annual report to the nation on
the status of cancer enables a comprehensive review
and analysis of the progress being made in diminish-
ing the cancer burden, highlighting the challenges
ahead, and focusing on timely issues such as health
disparities, cancer care, and specific segments of the
cancer continuum, from screening and risk behaviors
in healthy persons to quality of life for patients who
are dying from cancer. This year’s report provides the
most comprehensive description of cancer incidence
in the AI/AN population available to date and
highlights several areas of progress in the general
population, notably the continued decline in cancer
mortality rates and the recent decline in female
breast cancer incidence rates after 20 years of in-
creases. The commitment and leadership from the
national organizations to the state cancer registries,
vital statistics systems, and local hospitals and other
medical facilities that support the infrastructure are
critical components that provide information for
cancer control, public policy, and identifying impor-
tant avenues for future research.
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